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INTRODUCTION 
 
The increasing use of plant medicines in Europe needs a shared methodology to determine the 
toxicity and daily exposure level to these drugs. For this reason, the European regulatory Agencies 
have undertaken a study that could meet popular uses and toxicological research in different 
countries of the Union. Here we list some examples of the most used herbal drug classes where 
we propose a decision-making process based on the plant’s characteristics, their content in active 
principles and on the basis of the present scientific pharmacological and toxicological literature. 
The proposed decision tree actually makes easier for the assessor to quickly and accurately 
evaluate the accredited indexes for risk and toxicity assessment based on the preclinical literature 
data and using the correct classification that some of them may have because they are already 
present in medicinal products or used as food. Here is reported a systematic approach to assessing 
the toxicity of plant drugs based on their phytochemical composition and the conscious use of the 
parameters (e.g. NOEL, NOAEL, TTC etc.), which must be applied appropriately to the protection of 
both the manufacturer and the final consumer. 
Before discussing the systematic approach, it is critical to have e view of the regulatory terms and 
guidelines which must be respected in order to obtain a marketing authorization and the different 
legal basis that a product of botanical origin can make use of the “full dossier” application request 
to the applicant to provide a multitude of documents. To make this application easier all those 
documents follow the Common Technical document grid (CTD) which were agreed in November 
2000 within the International Conference on Harmonization (ICH) and is summarized in the 
following image. 
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1. Regulatory 
The Common Technical Document is organized into five modules. The content of Module 1 is 
defined by the European Commission in consultation with the competent authorities of the 
Member States, the European Agency for the Evaluation of Medicinal Products and interested 
parties. Concerning the structure of Modules 2, 3, 4, and 5 they are common for all ICH regions. 
Administrative, regional or national information is provided in Module 1. This module contains the 
specific EU-requirements for the administrative data (e.g. the application form, the proposed 
summary of product characteristics, labelling and package leaflet, etc.).  
Module 2 contains high level summaries (the Quality Overall Summary, the Non-Clinical Overview 
/Summaries, and the Clinical Overview/Summaries), which must be prepared by suitably qualified 
and experienced persons (experts). Although the term “Expert Report” must be maintained for 
legal reasons, the content is expected to be given in the Quality Overall Summary, the Non-Clinical 
Overview/Summaries, and the Clinical Overview/Summaries documents. Old Expert Reports are 
now replaced by Module 2. The experts have to sign and add brief information on their 
educational background and specific expertise in a special section in Module 1.4.  
Chemical, Pharmaceutical and Biological documentation is provided by Module 3. This information 
should be structured as described in Guideline M4Q (M4Q (R1): QUALITY Module 2: Quality 
Overall Summary (QOS) Module 3: Quality The section of the application covering chemical and 
pharmaceutical data including data for biological/ biotechnological products).  
The documentation on the Toxicological and Pharmacological Tests performed on drug/active 
substance and a drug/medicinal product is provided in the Non-Clinical Written Summaries (from 
Module 2) and by the Non-Clinical Study Reports (Module 4). These reports should be presented in 
the order described in Guideline M4S (M4S (R2): SAFETY Nonclinical Summaries and Organization 
of Module 4 The non-clinical section of the application).  
The documentation on the Clinical Trials performed on the drug/medicinal product is provided in 
the Clinical Written Summaries (from Module 2) and in the Clinical Study Reports (Module 5). 
These reports should be presented in the order described in Guideline M4E (M4E (R1): EFFICACY 
Module 2: Clinical Overview and Clinical Summary Module 5 Clinical Study Reports The clinical 
section of the Application).  
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Shifting the attention on the part concerning the safety, here we report how to analyze the 
appropriate section of the module 2 and 4 underlining the information that should be provided by 
the applicant. 
Module 2.4 Nonclinical Overview  
Nonclinical Overview  
The Nonclinical Overview should provide an integrated overall analysis of the information in the 
Common Technical Document. In general, the Nonclinical Overview should not exceed about 30 
pages.  
General Aspects  
The Nonclinical Overview should present an integrated and critical assessment of the 
pharmacologic, pharmacokinetic, and toxicologic evaluation of the pharmaceutical. Where 
relevant guidelines on the conduct of studies exist, these should be taken into consideration, and 
any deviation from these guidelines should be discussed and justified. The nonclinical testing 
strategy should be discussed and justified. There should be comment on the GLP status of the 
studies submitted. Any association between nonclinical findings and the quality characteristics of 
the human pharmaceutical, the results of clinical trials, or effects seen with related products 
should be indicated, as appropriate.  
Except for biotechnology-derived products, an assessment of the impurities and degradants 
present in the drug substance and product should be included along with what is known of their 
potential pharmacologic and toxicologic effects. This assessment should form part of the 
justification for proposed impurity limits in the drug substance and product, and be appropriately 
cross-referenced to the quality documentation. The implications of any differences in the chirality, 
chemical form, and impurity profile between the compound used in the nonclinical studies and 
the product to be marketed should be discussed. For biotechnology-derived products, 
comparability of material used in nonclinical studies, clinical studies, and proposed for marketing 
should be assessed. If a drug product includes a novel excipient, an assessment of the information 
regarding its safety should be provided.  
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Relevant scientific literature and the properties of related products should be taken into account. 
If detailed references to published scientific literature are to be used in place of studies conducted 
by the applicant, this should be supported by an appropriate justification that reviews the design 
of the studies and any deviations from available guidelines. In addition, the availability of 
information on the quality of batches of drug substance used in these referenced studies should 
be discussed.  
The Nonclinical Overview should contain appropriate reference citations to the Tabulated 
Summaries, in the following format: (Table X.X, Study/Report Number).  
Content and Structural Format  
The Nonclinical Overview should be presented in the following sequence:  
Overview of the nonclinical testing strategy Pharmacology 
Pharmacokinetics 
Toxicology  
Integrated overview and conclusions  
List of literature references  
Studies conducted to establish the pharmacodynamic effects, the mode of action, and potential 
side effects should be evaluated and consideration should be given to the significance of any 
issues that arise.  
The assessment of the pharmacokinetic, toxicokinetic, and metabolism data should address the 
relevance of the analytical methods used, the pharmacokinetic models, and the derived 
parameters. It might be appropriate to cross-refer to more detailed consideration of certain issues 
within the pharmacology or toxicology studies (e.g. impact of the disease states, changes in 
physiology, anti-product antibodies, cross-species consideration of toxicokinetic data). 
Inconsistencies in the data should be discussed. Inter-species comparisons of metabolism and 
systemic exposure comparisons in animals and humans (AUC, Cmax, and other appropriate 
parameters) should be discussed and the limitations and utility of the nonclinical studies for 
prediction of potential adverse effects in humans highlighted.  
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The onset, severity, and duration of the toxic effects, their dose-dependency and degree of 
reversibility (or irreversibility), and species- or gender-related differences should be evaluated and 
important features discussed, particularly with regard to:  
• pharmacodynamics  
• toxic signs  
• causes of death  
• pathologic findings  
• genotoxic activity - the chemical structure of the compound, its mode of action, and its 
relationship to known genotoxic compounds  
• carcinogenic potential in the context of the chemical structure of the compound, its 
relationship to known carcinogens, its genotoxic potential, and the exposure data  
• the carcinogenic risk to humans - if epidemiologic data are available, they should be taken 
into account  
• fertility, embryofetal development, pre-and post-natal toxicity  
• studies in juvenile animals  
• the consequences of use before and during pregnancy, during lactation, and during 
pediatric development  
• local tolerance  
• other toxicity studies/ studies to clarify special problems  
The evaluation of toxicology studies should be arranged in a logical order so that all relevant data 
elucidating a certain effect / phenomenon are brought together. Extrapolation of the data from 
animals to humans should be considered in relation to:  
• animal species used  
• numbers of animals used  
• routes of administration employed  
• dosages used  
• duration of treatment or of the study  
• systemic exposures in the toxicology species at no observed adverse effect levels and at 
toxic doses, in relation to the exposures in humans at the maximum recommended human 
dose. Tables or figures summarising this information are recommended.  
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• the effect of the drug substance observed in nonclinical studies in relation to that expected 
or observed in humans  
If alternatives to whole-animal experiments are employed, their scientific validity should be 
discussed.  
The Integrated Overview and Conclusions should clearly define the characteristics of the human 
pharmaceutical as demonstrated by the nonclinical studies and arrive at logical, well-argued 
conclusions supporting the safety of the product for the intended clinical use. Taking the 
pharmacology, pharmacokinetics, and toxicology results into account, the implications of the 
nonclinical findings for the safe human use of the pharmaceutical should be discussed (i.e., as 
applicable to labeling).  
2.5.5 Overview of Safety  
The purpose of this section is to provide a concise critical analysis of the safety data, noting how 
results support and justify proposed prescribing information. A critical analysis of safety should 
consider:  
• adverse effects characteristic of the pharmacological class. Approaches taken to monitor 
for similar effects should be described.  
• special approaches to monitoring for particular adverse events (e.g., ophthalmic, QT 
interval prolongation).  
• relevant animal toxicology and product quality information. Findings that affect or could 
affect the evaluation of safety in clinical use should be considered.  
• the nature of the patient population and the extent of exposure, both for test drug and 
control treatments. Limitations of the safety database, e.g., related to inclusion/exclusion 
criteria and study subject demographics, should be considered, and the implications of 
such limitations with respect to predicting the safety of the product in the marketplace 
should be explicitly discussed.  
• common and non-serious adverse events, with reference to the tabular presentations of 
events with the test drug and with control agents in the Clinical Summary. The discussion 
should be brief, focusing on events of relatively high frequency, those with an incidence 
higher than placebo, and those that are known to occur in active controls or other 
 8 
members of the therapeutic class. Events that are substantially more or less common or 
problematic (considering the duration and degree of the observed events) with the test 
drug than with active controls are of particular interest.  
• serious adverse events (relevant tabulations should be cross-referenced from the Clinical 
Summary). This section should discuss the absolute number and frequency of serious 
adverse events, including deaths, and other significant adverse events (e.g., events leading 
to discontinuation or dose modification), and should discuss the results obtained for test 
drug versus control treatments. Any conclusions regarding causal relationship (or lack of 
this) to the product should be provided. Laboratory findings reflecting actual or possible 
serious medical effects should be considered.  
• similarities and differences in results among studies, and their effect upon the 
interpretation of the safety data.  
• any differences in rates of adverse events in population subgroups, such as those defined 
by demographic factors, weight, concomitant illness, concomitant therapy, or polymorphic 
metabolism.  
• relation of adverse events to dose, dose regimen, and treatment duration.  
• long-term safety.  
• methods to prevent, mitigate, or manage adverse events.  
• reactions due to overdose; the potential for dependence, rebound phenomena and abuse, 
or lack of data on these issues.  
• world-wide marketing experience. The following should be briefly discussed:  
- the extent of the world-wide experience, 
- any new or different safety issues identified,  
- any regulatory actions related to safety.  
• support for the applicability to the new region of data generated in another region, where 
appropriate (guideline ICH E5).  
2.6.6 Toxicology written summary  
The sequence of the Toxicology Written Summary should be as follows:  
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• Brief Summary  
• Single-Dose Toxicity  
• Repeat-Dose Toxicity  
• Genotoxicity  
• Carcinogenicity  
• Reproductive and Developmental Toxicity  
• Studies in Juvenile Animals  
• Local Tolerance  
• Other Toxicity Studies  
• Discussion and Conclusions  
• Tables and Figures (either here or included in text)  
2.6.6.1 Brief Summary  
The principal findings from the toxicology studies should be briefly summarized in a few pages 
(generally not more than 6). In this section, the extent of the toxicologic evaluation can be 
indicated by the use of a table listing the principal toxicologic studies (results should not be 
presented in this table), for example:  
Toxicology programme  
The scope of the toxicologic evaluation should be described in relation to the proposed clinical 
use. A comment on the GLP status of the studies should be included.  
2.6.6.2 Single-Dose Toxicity  
The single-dose data should be very briefly summarised, in order by species, by route. In some 
instances, it may be helpful to provide the data in the form of a table.  
Study type and 
duration 
Route of 
administration 
Species  
Compound 
administered*  
Single-dose toxicity po and iv Rat and mouse  Parent drug 
Single-dose toxicity po and iv Rat and mouse  Metabolite X 
Repeat-dose toxicity     
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1 month  po Rat and dog Parent drug 
6 months  po Rat  “        ” 
9 months po dog “        ” 
etc.    
* This column required only if metabolite(s) are investigated.  
2.6.6.3 Repeat-Dose Toxicity (including supportive toxicokinetics evaluation)  
Studies should be summarised in order by species, by route, and by duration, giving brief details of 
the methodology and highlighting important findings (e.g., nature and severity of target organ 
toxicity, dose (exposure)/response relationships, no observed adverse effect levels, etc.). Non- 
pivotal studies can be summarized in less detail (pivotal studies are the definitive GLP studies 
specified by ICH Guideline M3).  
2.6.6.4 Genotoxicity  
Studies should be briefly summarised in the following order:  
• in vitro non-mammalian cell system  
• in vitro mammalian cell system  
• in vivo mammalian system (including supportive toxicokinetics evaluation)  
• other systems  
2.6.6.5 Carcinogenicity (including supportive toxicokinetics evaluations)  
A brief rationale should explain why the studies were chosen and the basis for high-dose selection. 
Individual studies should be summarised in the following order:  
• Long-term studies (in order by species; including range-finding studies that cannot 
appropriately be included under repeat-dose toxicity or pharmacokinetics)  
• Short- or medium-term studies (including range-finding studies that cannot appropriately 
be included under repeat-dose toxicity or pharmacokinetics)  
• Other studies  
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2.6.6.6 Reproductive and Developmental Toxicity (including range-finding studies and 
supportive toxicokinetics evaluations)  
Studies should be summarised in the following order, giving brief details of the methodology and 
highlighting important findings:  
• Fertility and early embryonic development  
• Embryo-fetal development  
• Prenatal and postnatal development, including maternal function  
• Studies in which the offspring (juvenile animals) are dosed and/or further evaluated, if  
such studies have been conducted. 
If modified study designs are used, the sub-headings should be modified accordingly.  
2.6.6.7 Local Tolerance  
If local tolerance studies have been performed, they should be summarised in order by species, by 
route, and by duration, giving brief details of the methodology and highlighting important findings.  
2.6.6.8 Other Toxicity Studies (if available)  
If other studies have been performed, they should be summarised. When appropriate, the 
rationale for conducting the studies should be provided.  
• Antigenicity  
• Immunotoxicity  
• Mechanistic studies (if not reported elsewhere)  
• Dependence  
• Studies on metabolites  
• Studies on impurities  
• Other studies  
2.6.6.9 Discussion and Conclusions  
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This section should provide an opportunity to discuss the toxicologic evaluation and the 
significance of any issues that arise. Tables or figures summarizing this information are 
recommended.  
Module 4 – Nonclinical study report 
The appropriate location for individual-animal data is in the study report or as an appendix to the 
study report.  
4.1 Table of contents of module 4  
A Table of Contents should be provided that lists all of the nonclinical study reports and gives the 
location of each study report in the Common Technical Document.  
4.2 Study reports  
The study reports should be presented in the following order:  
4.2.1 Pharmacology  
1. 4.2.1.1 Primary Pharmacodynamics  
2. 4.2.1.2 Secondary Pharmacodynamics  
3. 4.2.1.3 Safety Pharmacology  
4. 4.2.1.4 Pharmacodynamic Drug Interactions  
4.2.2 Pharmacokinetics  
5. 4.2.2.1 Analytical Methods and Validation Reports (if separate reports are available)  
6. 4.2.2.2 Absorption  
7. 4.2.2.3 Distribution  
8. 4.2.2.4 Metabolism  
9. 4.2.2.5 Excretion  
10. 4.2.2.6 Pharmacokinetic Drug Interactions (nonclinical)  
11. 4.2.2.7 Other Pharmacokinetic Studies  
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4.2.3 Toxicology  
4.2.3.1 Single-Dose Toxicity (in order by species, by route)  
4.2.3.2 Repeat-Dose Toxicity (in order by species, by route, by duration; including 
supportive toxicokinetics evaluations)  
4.2.3.3 Genotoxicity  
4.2.3.3.1 In vitro  
4.2.3.3.2 In vivo (including supportive toxicokinetics evaluations)  
4.2.3.4.1 Long-term studies (in order by species; including range- finding 
studies that cannot appropriately be included under repeat-dose 
toxicity or pharmacokinetics) 
4.2.3.4.2 Short- or medium-term studies (including range-finding studies that 
cannot appropriately be included under repeat- dose toxicity or 
pharmacokinetics)  
4.2.3.4.3 Other studies 
4.2.3.5 Reproductive and Developmental Toxicity (including range-finding studies and    
supportive toxicokinetics evaluations) (If modified study designs are used, the 
following sub-headings should be modified accordingly.)  
4.2.3.5.1 Fertility and early embryonic development 
4.2.3.5.2 Embryo-fetal development 
4.2.3.5.3 Prenatal and postnatal development, including maternal function 
4.2.3.5.4 Studies in which the offspring (juvenile animals) are dosed and/or 
further evaluated.  
4.2.3.6 Local Tolerance  
4.2.3.7 Other Toxicity Studies (if available)  
4.2.3.7.1 Antigenicity 
4.2.3.7.2 Immunotoxicity 
4.2.3.7.3 Mechanistic studies (if not included elsewhere)  
4.2.3.7.4 Dependence 
4.2.3.7.5 Metabolites 
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4.2.3.7.6 Impurities 
4.2.3.7.7 Other  
4.3 Literature references  
That safety information should be provided by the applicant for a “full dossier” application, 
however some product, (especially those made by plant) can take advantage of other kind of 
application provided by the European Directive 2001/83/EC of 6 November 2001. Particularly the 
art. 16a and the art. of the above-mentioned Directive ratify the possibility to submit a dossier 
under the “traditional use” or “well-established use”. Due the choice of the applicant concerning 
the legal basis chosen for the product formulation also the information required should be 
modified. 
Article 16a 
1. A “simplified registration” procedure (hereinafter ‘traditional-use registration’) is hereby 
established for herbal medicinal products which fulfil all of the following criteria:  
(a)  they have indications exclusively appropriate to traditional herbal medicinal products 
which, by virtue of their composition and purpose, are intended and designed for use 
without the supervision of a medical practitioner for diagnostic purposes or for 
prescription or monitoring of treatment;  
(b) they are exclusively for administration in accordance with a specified strength and 
posology;  
(c) they are an oral, external and/or inhalation preparation;  
(d) the period of traditional use as laid down in Article 16c(1)(c) has elapsed;  
(e) the data on the traditional use of the medicinal product are sufficient; in particular the 
product proves not to be harmful in the specified conditions of use and the 
pharmacological effects or efficacy of the medicinal product are plausible on the basis of 
long-standing use and experience.  
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Concerning the safety information the article 16c 1. (b), (c), (d) and 2. must be considered: 
(b) any authorization or registration obtained by the applicant in another Member State, or 
in a third country, to place the medicinal product on the market, and details of any 
decision to refuse to grant an authorization or registration, whether in the Community or a 
third country, and the reasons for any such decision;  
(c) bibliographical or expert evidence to the effect that the medicinal product in question, 
or a corresponding product has been in medicinal use throughout a period of at least 30 
years preceding the date of the application, including at least 15 years within the 
Community. At the request of the Member State where the application for traditional-use 
registration has been submitted, the Committee for Herbal Medicinal Products shall draw 
up an opinion on the adequacy of the evidence of the long-standing use of the product, or 
of the corresponding product. The Member State shall submit relevant documentation 
supporting the referral;  
(d) a bibliographic review of safety data together with an expert report, and where 
required by the competent authority, upon additional request, data necessary for 
assessing the safety of the medicinal product.  
2. A corresponding product, as referred to in paragraph 1(c), is characterized by having the same 
active ingredients, irrespective of the excipients used, the same or similar intended purpose, 
equivalent strength and posology and the same or similar route of administration as the medicinal 
product applied for.  
Referring to the “well-established use” submission the Part II of the Directive 2001/83/EC declaim: 
Some medicinal products present specific features which are such that all the requirements of the 
marketing authorization application dossier as laid down in Part I of this Annex need to be 
adapted. To take account of these particular situations, an appropriate and adapted presentation 
of the dossier shall be followed by applicants.  
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1. Well-established medicinal use 
For medicinal products, the active substance(s) of which has/have a ‘well-established medicinal 
use’ as referred to Article 10(1)(a)(ii), with recognized efficacy and an acceptable level of safety, 
the following specific rules shall apply.  
The applicant shall submit Modules 1, 2 and 3 as described in part I of this Annex.  
For Modules 4 and 5, a detailed scientific bibliography shall address non-clinical and clinical 
characteristics.  
The following specific rules shall apply in order to demonstrate the well-established medicinal use:  
a) Factors which have to be taken into account in order to verify a well-established 
medicinal use of constituents of medicinal products are:  
— the time over which a substance has been used,  
— quantitative aspects of the use of the substance,  
—the degree of scientific interest in the use of the substance (reflected in the 
published scientific literature) and 
— the coherence of scientific assessments.  
Therefore, different periods of time may be necessary for verify well-established use of different 
substances. In any case, however, the period of time required for establishing a well-established 
medicinal use of a constituent of a medicinal product must not be less than one decade from the 
first systematic and documented use of that substance as a medicinal product in the Community.  
b) The documentation submitted by the applicant should cover all aspects of the safety 
and/or efficacy assessment and must include or refer to a review of the relevant 
literature, taking into account pre- and post-marketing studies and published scientific 
literature concerning experience in the form of epidemiological studies and in particular 
of comparative epidemiological studies. All documentation, both favorable and 
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unfavorable, must be communicated. With respect to the provisions on ‘well-established 
medicinal use’ it is in particular necessary to clarify that ‘bibliographic reference’ to other 
sources of evidence (post marketing studies, epidemiological studies, etc.) and not just 
data related to tests and trials may serve as a valid proof of safety and efficacy of a 
product if an application explains and justifies the use of these sources of information 
satisfactorily.  
2. Toxicology 
The traditional definition of toxicology is "the science of poisons". As our understanding of how 
various agents can cause harm to humans and other organisms, a more descriptive definition of 
toxicology is "the study of the adverse effects of chemicals or physical agents on living organisms". 
The historical development of toxicology began with early cave dwellers who recognized 
poisonous plants and animals and used their extracts for hunting or in warfare. By 1500 B.C., 
written recordings indicated that hemlock, opium, arrow poisons, and certain metals were used to 
poison enemies or for state executions. With time, poisons became widely used and with great 
sophistication. Notable poisoning victims include Socrates, Cleopatra, and Claudius. By the time of 
the Renaissance and Age of Enlightenment, certain concepts fundamental to toxicology began to 
take shape. The studies of Paracelsus (~1500 A.D.) and Orfila (~1800 A.D.) are well known. 
Paracelsus determined that specific chemicals were actually responsible for the toxicity of a plant 
or animal poison. He also documented that the body's response to those chemicals depended on 
the dose received. His studies revealed that small doses of a substance might be harmless or 
beneficial whereas larger doses could be toxic. This is now known as the dose-response 
relationship, a major concept of toxicology. Paracelsus was one of the founders of modern 
toxicology. His best-known quote: “All substances are poisons; it is the dose that makes the 
poison.” Orfila, a Spanish physician, is often referred to as the founder of toxicology. It was Orfila 
who first prepared a systematic correlation between the chemical and biological properties of 
poisons of the time. He demonstrated effects of poisons on specific organs by analyzing autopsy 
materials for poisons and their associated tissue damage. The 20th century is marked by an 
advanced level of understanding of toxicology. DNA and various biochemicals that maintain body 
functions were discovered. Our level of knowledge of toxic effects on organs and cells is now being 
revealed at the molecular level. It is recognized that virtually all toxic effects are caused by 
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changes in specific cellular molecules and biochemical. Now toxicology can be divided in tree 
macro areas: 
Molecular Toxicology concerning the Identification of biochemical and cellular molecular 
mechanisms by which substances exert their toxic effect. 
Descriptive Toxicology targeted to produce the information necessary for the safety assessment 
(e.g. Pre-clinical studies, assessment of the LD50) 
Regulatory Toxicology concerning the guidelines and other documents issued by regulatory 
Agency in FDA, EMA to assess drugs and food about safety. 
Before discussing and analyze how to use a toxicological data here we report some basic 
information concerning definitions: 
Xenobiotic is the general term that is used for a foreign substance taken into the body. It is 
derived from the Greek term xeno which means "foreigner." Xenobiotics may produce beneficial 
effects (such as a pharmaceuticals) or they may be toxic (such as lead). As Paracelsus proposed 
centuries ago, dose differentiates whether a substance will be a remedy or a poison. A xenobiotic 
in small amounts may be non-toxic and even beneficial but when the dose is increased, toxic and 
lethal effects may result.  
Toxicants 
Substances that produce adverse biological effects of any nature. May 
be chemical or physical in nature. Effects may be of various nature 
(acute, chronic, etc.) 
Toxins 
Specific proteins produced by living organisms (mushrooms, bacteria, 
etc.) 
Poisons 
Toxicants that cause immediate death or illness when experienced in 
very small amounts 
Toxicant, toxin, and poison are often used interchangeably in the literature; however, there are 
subtle differences as indicated in the table. Toxic substances may be systemic toxins or organ 
toxins. A systemic toxin is one that affects the entire body or many organs rather than a specific 
site. For example, potassium cyanide is a systemic toxicant in that it affects virtually every cell and 
organ in the body by interfering with the cell's ability to utilize oxygen. Toxicants may also affect 
only specific tissues or organs while not producing damage to the body as a whole. These specific 
sites are known as the target organs or target tissues.  
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Some examples: Benzene is a specific organ toxin in that it is primarily toxic to the blood-forming 
tissues. Lead is also a specific organ toxin; however, it has three target organs (central nervous 
system, kidney, and hematopoietic system).  
A toxic agent is anything that can produce an adverse biological effect. It may be chemical, 
physical, or biological in form. For example, toxic agents may be chemical (such as cyanide), 
physical (such as radiation) and biological (such as snake venom).  
A distinction is made for diseases due to biological organisms. Those organisms that invade and 
multiply within the organism and produce their effects by biological activity are not classified as 
toxic agents. An example of this is a virus that damages cell membranes resulting in cell death.  
If the invading organisms excrete chemicals which is the basis for toxicity, the excreted substances 
are known as biological toxins. The organisms in this case are referred to as toxic organisms. An 
example is tetanus. Tetanus is caused by a bacterium, Clostridium tetani. The bacteria C. tetani 
itself does not cause disease by invading and destroying cells. Rather, it is a toxin that is excreted 
by the bacteria that travels to the nervous system that produces the disease.  
A toxic substance is simply a material which has toxic properties. It may be a discrete toxic 
chemical or a mixture of toxic chemicals. For example, lead chromate, asbestos, and gasoline are 
all toxic substances. Lead chromate is a discrete toxic chemical. Asbestos is a toxic material that 
does not consist of an exact chemical composition but a variety of fibers and minerals. Gasoline is 
also a toxic substance rather than a toxic chemical in that it contains a mixture of many chemicals. 
Toxic substances may not always have a constant composition. For example, the composition of 
gasoline varies with octane level, manufacturer, time of season, etc. Toxic substances may be 
systemic toxins or organ toxins. A systemic toxin is one that affects the entire body or many 
organs rather than a specific site. For example, potassium cyanide is a systemic toxicant in that it 
affects virtually every cell and organ in the body by interfering with the cell's ability to utilize 
oxygen. Toxicants may also affect only specific tissues or organs while not producing damage to 
the body as a whole. These specific sites are known as the target organs or target tissues.  
A toxicant may affect a specific type of tissue (such as connective tissue) that is present in several 
organs. The toxic site is then referred to as the target tissue.  
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There are many types of cells in the body and they can be classified in several ways.  
- basic structure (e.g., cuboidal cells) 
- tissue type (e.g., hepatocytes of the liver) 
- germinal cells (e.g., ova and sperm) 
- somatic cells (e.g., non-reproductive cells of the body)  
The main factors determining adverse effects are: intrinsic toxicity of the substance, dose, 
exposure conditions and response of host (such as detoxification abilities of the organism or the 
bioactivation). Dose by definition is the amount of a substance administered at one time. 
However, other parameters are needed to characterize the exposure to xenobiotics. The most 
important are the number of doses, frequency, and total time period of the treatment.  
Exposure dose The amount of a xenobiotic encountered in the enviroment 
Absorbed dose The actual amount of the exposed dose that enters the body 
Administered dose The quantity administered usually orally or by injection 
Total dose The sum of all individual doses 
Fractionating a total dose usually decreases the probability that the total dose will cause toxicity. 
The reason for this is that the body often can repair the effect of each subtoxic dose if sufficient 
time passes before receiving the next dose. In such a case, the total dose, harmful if received all at 
once, is non-toxic when administered over a period of time. For example, 30 mg of strychnine 
swallowed at one time could be fatal to an adult whereas 3 mg of strychnine swallowed each day 
for ten days would not be fatal. The dose-response relationship is a fundamental and essential 
concept in toxicology. It correlates exposures and the spectrum of induced effects. Generally, the 
higher the dose, the more severe the response. The dose-response relationship is based on 
observed data from experimental animal, human clinical, or cell studies.  
 
0
0.5
1
1.5
low response mean reponse higher responseIn
d
iv
id
u
al
 r
es
p
o
n
n
g 
(p
er
ce
n
t)
Dose-Effect Relationship
1 S.D.  (68%)
2 S.D. (95 %)
 21 
Knowledge of the dose-response relationship: 
- - establishes causality that the chemical has in fact induced the  
observed effects 
- - establishes the lowest dose where an induced effect occurs (the  
threshold effect) 
- - determines the rate at which injury builds up (the slope for the dose  
response).  
Within a population, the majority of responses to a toxicant are similar; however, a wide variance 
of responses may be encountered, some individuals are susceptible and others resistant. As 
demonstrated above, a graph of the individual responses can be depicted as a bell- shaped 
standard distribution curve. Dose responses are commonly presented as mean + 1 S.D. (standard 
deviation), which incorporates 68% of the individuals. The variance may also be presented as two 
standard deviations, which incorporates 95% of the responses. A large standard deviation 
indicates great variability of response. For example, a response of 12+5 mg indicates considerably 
more variability than 12+1 mg.  
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The dose-response curve normally takes the form of a sigmoid curve. It conforms to a smooth 
curve as close as possible to the individual data points. For most effects, small doses are not toxic. 
The point at which toxicity first appears is known as the threshold dose level. From that point, the 
curve increases with higher dose levels. In the hypothetical curve above, no toxicity occurs at 10 
mg whereas at 35 mg 100% of the individuals experience toxic effects. There is always a relation 
between dose and effect/response, but for some agents there is a threshold below which no 
effect occurs. A threshold for toxic effects occurs at the point where the body's ability to detoxify a 
xenobiotic or repair toxic injury has been exceeded. For most organs, there is a reserve capacity so 
that loss of some organ function does not cause decreased performance. For example, the 
development of cirrhosis in the liver may not result in a clinical effect until over 50% of the liver 
has been replaced by fibrous tissue. 
 
Knowledge of the shape and slope of the dose-response curve is extremely important in predicting 
the toxicity of a substance at specific dose levels. Major differences among toxicants may exist not 
only in the point at which the threshold is reached but also in the percent of population 
responding per unit change in dose (i.e., the slope). As illustrated above, Toxicant A has a higher 
threshold but a steeper slope than Toxicant B. Knowledge of the dose-response relationship 
permits one to determine whether exposure has caused an effect, threshold for the effect, and 
the rate of buildup of the effect with increasing dose levels. Rate of buildup of toxic effects is 
known as the "slope" of the dose-response curve.  
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MATHERIAL AND METHODS 
In the light of what has just been said the selection of the toxicological data should be as 
representative as possible of the final use of the product under assessment e.g. same route of 
administration, pharmaceutical form etc. In any case correction factors or, in the end the TTC 
(Threshold of Toxicological Concern) approach, could always be applied if no representative data 
have been founded. The complex composition of herbal preparations presents an additional 
challenge because it is not always possible to make or find an ad hoc study and that is why it is 
possible to avail of numerous toxicological parameters that allow to assess the reliability of the 
security data. The well-known toxicological parameters usually considered for the safety 
assessment requirements are NOEL (Non-Observed Effect Level), LHRD (Lowest Human 
Recommended Dose), DL50 (lethal dose 50), TTC e PDE (Permitted Daily Exposure). These 
parameters can be easily calculated or derivate from literature data. For plant used both in 
medicinal products and in food, the ADI (admitted daily intake) should be considered as parameter 
also because is used by WHO and other competent Authorities in safety food assessments (e.g. 
EFSA). 
In this complex evaluation process, the assessors can find a help in guidelines and the most used 
ones are published in the EMA website such as Guideline on setting health based exposure limits 
for use in risk identification in the manufacture of different medicinal products in shared facilities; 
guideline for residual solvents; Guideline on the limits of genotoxic on the impurities; updated on 
revision chapters 3 and 5 of the good manufacturing practices (GMP) guide: “dedicated facilities”; 
Guideline on specifications: test procedures and acceptance criteria for herbal substances, herbal 
preparations and herbal medicinal products/traditional herbal medicinal products, Guidance for 
Industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult 
healthy volunteers; Structure-based thresholds of toxicological concern (TTC): guidance for 
application to substances present at low levels in the diet. 
Here we suggest an overview of the safety requirements, raised by the enormous interest and 
growing market for medicinal products of botanical origin, that are contemplated in European 
pharmaceutical legislation, in order to apply a scheme that provides a practical method for 
assessing herbal substances and herbal preparations for which an adequate body of knowledge 
exists in the scientific literature and therefore without the must of needing an ad hoc study. This 
scheme uses the well-known toxicological parameters and the consistency of the obtained 
parameter is strongly influenced from the chosen datum. Usually to assess the risks related to 
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toxic substances were used experimental toxicology studies that are divided in: Acute toxicity 
studies, toxicity studies in the medium term (also called sub-acute or sub chronic) and long-term 
toxicity studies (also known as chronic toxicity studies) (C. Lu, Kacew 2002). Acute toxicity occurs 
almost immediately (hours/days) after an exposure. An acute exposure is usually a single dose or a 
series of doses received within a 24-hour period. Death is a major concern in cases of acute 
exposures. One example is that in 1989, 5,000 people died and 30,000 were permanently disabled 
due to exposure to methyl isocyanate from an industrial accident in Bhopal, India. Subchronic 
toxicity results from repeated exposure for several weeks or months. This is a common human 
exposure pattern for some pharmaceuticals and environmental agents. An example is that the 
ingestion of coumarines (blood thinners) for several weeks as a treatment for venous thrombosis 
can cause internal bleeding. Chronic toxicity represents cumulative damage to specific organ 
systems and takes many months or years to become a recognizable clinical disease. Damage due 
to subclinical individual exposures may go unnoticed. With repeated exposures or long-term 
continual exposure, the damage from these subclinical exposures slowly builds-up (cumulative 
damage) until the damage exceeds the threshold for chronic toxicity. Ultimately, the damage 
becomes so severe that the organ can no longer function normally and a variety of chronic toxic 
effects may result. Examples of chronic toxic effects are: cirrhosis in alcoholics who have ingested 
ethanol for several years; chronic kidney disease in workmen with several years exposure to lead; 
chronic bronchitis in long-term cigarette smokers. For a complete point of view, if that information 
has been investigated, also carcinogenicity, development toxicity and genetic toxicity should be 
analyzed.  
Carcinogenicity is a complex multistage process of abnormal cell growth and differentiation which 
can lead to cancer. At least two stages are recognized. They are initiation in which a normal cell 
undergoes irreversible changes and promotion in which initiated cells are stimulated to progress 
to cancer. Chemicals can act as initiators or promoters.  
Developmental toxicity pertains to adverse toxic effects to the developing embryo or fetus. This 
can result from toxicant exposure to either parent before conception or to the mother and her 
developing embryo-fetus. The three basic types of developmental toxicity are: Embryiolethality 
(failure to conceive, spontaneous abortion or stillbirth), embriotoxicity (growth retardation or 
delayed growth of specific organ system), teratogenicity (irreversible conditions that leave 
permanent birth defects in live offspring). Developmental toxicity should not be confused with the 
reproductive toxicity that involves toxicant damage to either the male or female reproductive 
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system and produce toxic effect such as decreased libido and impotence, infertility, chromosome 
abnormalities and births defect, etc.  
Genetic toxicity results from damage to DNA and altered genetic expression. This process is known 
as mutagenesis. The genetic change is referred to as a mutation and the agent causing the change 
as a mutagen. There are three types of genetic change: multistage process, initiation, promotion. 
The complete discussion and the analysis about the parameters that should be considered during 
the assessment of the safety aspects of a medicinal product of botanical origin with some practical 
examples of the application of the formulas to calculate parameters such as PDE are provided in 
“2.PDE” section. 
 
1. NOEL and NOAEL 
 Here below the formulas and their respective correction factors are analyzed:  
The NOEL is the maximum dose that did not cause any observable effect, the NOAEL (No 
Observable Adverse Effect Level) is the dose at which no observed adverse effects are evaluable, 
the LOEL (Lowest Observed Effect Level) is the lowest dose level (exposure) in which Observed 
Effect, the LOAEL (Lowest Observed Adverse Effect Level) is the lowest dose that show a 
detectable adverse effect and FEL (Frank Effect Level) level of exposure that produces 
unmistakable and irreversible effects (such as mortality or impairment) All these parameters are 
generally expressed in mg/kg and/or mg/kg body weight/day (in general are also known the 
corresponding exposure values in terms of Cmax and AUC). It’s really important to underline the 
difference from NOEL to NOAEL: the NOAEL is not the same as the no observed effect level 
(NOEL), which refers to any effect, not just an adverse one, although in some cases the two might 
be identical. The definition of the NOAEL, in contrast to that of NOEL, reflects the view that some 
effects observed in the animal may be acceptable pharmacodynamic actions of the therapeutic 
environment and may not raise a safety concern. The differences between NOEL and NOAEL are 
shown also in the formulas for the 
calculation that are the following: 
 
NOAEL = RfD (Acute Reference Dose) x UF (Uncertain Factor) or ADI x UF1 
 
NOEL = DL50 x Animal Weight / (UF) 200 - 3000 
                                                      
1 Usually significant NOAELs and LOAELs are obtained directly by the toxicological study rather than calculated 
 
 26 
 
UF is an empirical uncertainty factor, to obtain the toxicologically acceptable dose (Belitz, Grosch 
et. al. 2009). This is calculated and assigned by an expert judgment in force of the data and the 
existence in literature of an extensive knowledge of the substance in analysis. The minimum value 
of UF is 200 because 10 is the inter-species variability and another UF of 10 for intra-species 
variability. Now, considering the quality of the data, the absence of data about the chronic toxicity 
and the severity of the effect it is possible to have an additional factor of between 2-30 by 
multiplying with the previously obtained UF. The choice of these factors depends on the overall 
assessment of the available data and is based on an “expert judgment”. Every assessor could 
decide to apply different UFs, this depend on the finished product’s characteristics such as the 
route of administration, the issue to treat, the intrinsic toxicity of the substances under 
assessment; anyway, it is important to note that each different approach for the same product 
could be correct under an adequate scientific rational. The UF (as many default values) are under 
statistic rules such as inferential statistic and then anytime an experimental data is available in 
literature it must be considered.  
 
2. PDE 
Regarding the PDE (Permitted Daily Exposure) approach it could be calculated by the following 
formula: 
 
 
F1: a factor (between 2 and 12) which takes account of the extrapolation between species; F2: a factor of 10, which takes into account the 
variability between individuals; F3: a factor of 10, which takes account of the short-term toxicity studies with repeated doses e.g., Less than 4 
weeks; F4: a factor (1-10) that can be applied in case of severe toxicity, e.g. non-genotoxic carcinogenicity, neurotoxicity or teratogenicity; F5: a 
factor that no effect can be applied if it has not been established.2  
 
For the same substance, there could be available different values of ADIs and PDEs the first 
parameter is related to an intake the other is related to an exposure, indeed the PDE is defined as 
a pharmaceutically acceptable intake of residual solvents and then is more restrictive. For the 
purposes of calculation, when is available only the LOEL, a factor of up to 10 may be used 
depending on the severity of the toxicity. 
                                                      
2 For the exact factors, please see the document: Guideline on the Limits of Genotoxic on the Impurities, EMEA/CHMP/QWP/251344/2006 
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NOEL/F1 is equivalent to another toxicological parameter called HED (Human Equivalent Dose), 
that just represent the extrapolation. 
It should be noted that the PDE is more restrictive than the NOEL approach indeed one of its main 
application is mentioned in the guideline of “cleaning validation” to evaluate residual impurities, 
so is referred to substances that should not be in the finished product or something that should be 
avoided. About the PDE calculation, if different critical side effects were identified for the 
substance under assessment, the calculation of multiple values of PDEs should be considered and 
a decision as regards the most appropriate PDE must be made with an appropriate justification. 
Usually, it will use the lowest value of PDE. Different administration routes, except in exceptional 
cases, change the bioavailability. If there are obvious differences (>40%), it is necessary, therefore, 
to apply correction factors. The correction factors for route-to-route extrapolation should 
preferably be based on human data. If these data are unavailable, it is possible to proceed, by 
example extrapolating from the route of oral administration to the inhalation one, assuming 100% 
of the bioavailability of the substance as worst case. Consequently, the derived PDE based on oral 
data can be corrected by multiplying the oral absorption percentage for 100% inhalation. 
Unfortunately, it is not always possible to find a toxicological data in literature that is 
representative of the substance for which safety is to be assessed, especially when we are talking 
about of a pool of substances like a botanical fluid extract. In this case, the phytocomplex should 
be considered as representative for the toxicity unless the toxicity of the other components, 
different by the most potentially toxic one, is well known and negligible. In the worst case, not 
even the phytochemistry composition of the product under assessment is available and then the 
most restrictive approach (TTC value of 0,15 g/person) provided by Kroes et al. 2004 and Cramer 
et. Al 1978 should be applied. About those issues can be very useful the “Class structure” 
published by Cramer et al. 1978 which help to understand the most appropriate value of TTC to 
apply also in absence of toxicological data. 
 
3. TTC 
The threshold of toxicological concern (TTC) is defined as a level of human intake or exposure 
considered to be of negligible risk, despite the absence of chemical-specific toxicity data. 
The TTC is a pragmatic risk assessment tool that is based on the principle of establishing a human 
exposure threshold value for all chemicals, below which there is a very low probability of an 
appreciable risk to human health. In 1978 Cramer proposed (Cramer et al, 1978) a decision tree 
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for the application of the TTC concept to non-cancer endpoints. This is probably the most 
commonly used approach for classifying and ranking chemicals on the basis of their expected level 
of oral toxicity and this approach could be considered as a priority setting tool in the safety 
assessment of food additives which would make expert judgments more transparent, explicit and 
rational, and thus more reproducible and trustworthy. The scheme was derived from the authors’ 
earlier experience in classifying food flavors (Oser and Hall, 1977) and their subsequent work in 
evaluating a range of carcinogens, pesticides and industrial chemicals. The original Cramer 
classification consists in three different classes (I, II and III): 
Class I. Substances with simple chemical structures and for which efficient modes of metabolism 
exist, suggesting a low order of oral toxicity. 
Class II. Substances that possess structures that are less innocuous than class I substances, but do 
not contain structural features suggestive of toxicity like those substances in class III. 
Class III. Substances with chemical structures that permit no strong initial presumption of safety or 
may even suggest significant toxicity or have reactive functional groups. 
Recently, March 2016, the WHO and EFSA published a document concerning the application of the 
TTC approach and the Cramer’s scheme where is possible to read “The expert group concluded 
that the currently available information do not warrant major revisions to the Cramer scheme. The 
scheme is well suited for its intended purpose and when used in conjunction with the associated 
TTC values is protective. The group acknowledged that the sorting process of the Cramer decision 
scheme does work, is reproducible and the TTC values have been substantiated by post hoc 
comparison with numerous newer databases. In consequence, the expert group concluded that 
there is no scientifically-based justification for major restructuring of the decision scheme.  The 
Expert group recommended minor suggestions to modify the Cramer decision scheme to remove 
ambiguity, improve its clarity and to harmonize with the electronic tool Toxtree. The expert group 
recognized that there are a number of efforts underway, including those of the US Food and Drug 
Administration (FDA) and the International Organization of the Flavour Industry (IOFI), that 
propose significant modifications to the Cramer decision scheme, indicating that the developers 
interpret a need for revision. However, major modification to and restructuring of the Cramer 
decision scheme could result in a situation in which the original TTC values derived by Munro et al. 
(1996) and subsequently substantiated using different databases may be altered, and the 
implications for existing safety assessments need to be evaluated. Because the Cramer decision 
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scheme has been applied for the evaluation of flavouring agents for over 15 years, there is a need 
for broad acceptance of any future changes”.3 
The Threshold of Toxicological Concern, as said before, is an approach that can be used in the 
absence of chemical-specific toxicity data. It is based on the establishment of levels of human 
exposure (TTCs) that would not represent a safety concern using toxicological data for other 
chemicals sharing some structural similarities. The approach does not involve quantitative 
structure–activity relationships (QSAR) for specific endpoints but rather is based on the 
distribution of potencies for chemicals that share similar broad structural characteristics with the 
chemical under evaluation. In principle, the TTC approach can be considered for the safety 
evaluation of any chemical, which is not covered by the exclusion criteria in the current TTC 
approach, for which information on the chemical structure is available and for which an estimate 
of the extent of human exposure can be made. It allows an assessment of whether human 
exposure is so low that a more in-depth evaluation is not needed, or if chemical-specific toxicity 
data and/or control of human exposure are required. The TTC values can also be used to set an 
upper limit for human exposure for a chemical in the absence of intake data. The history of the 
TTC, the supporting databases and the extension of the original concept have been considered in 
numerous papers (Barlow et al., 2001; Brown et al., 2009; Cheeseman et al., 1999; Gold et al., 
2005; Kroes et al., 2004, 2007; Munro et al., 1996, 2008; SCCP, 2008). The approach has been 
controversial because it seeks to provide risk characterization advice in the absence of the usual 
toxicity database; the validity of the approach is critically dependent on the validity of the 
databases used to derive the TTC values.  
The TTC evolved following a review by Munro (1990) of the Threshold of Regulation (TOR), which 
is being used by the US Food and Drug Administration in the context of regulating food contact 
materials with low exposures and relates to a dietary concentration giving an intake of 1.5 μg per 
person per day, equivalent to 0.025 μg/kg body weight (bw) per day (US FDA, 1993). The TOR was 
derived by low-dose extrapolation of carcinogenicity data from animal studies to define human 
exposures associated with an upper-bound estimate of one in a million-cancer risk (US FDA, 1993; 
Munro, 1990). The TOR of 1.5 μg per person per day was considered to provide an adequate 
margin of safety for other forms of toxicity for chemicals that do not have a structural alert for 
genotoxicity/DNA reactivity. This approach led to the development of TTC values for non-cancer 
                                                      
3 Review of the Threshold of Toxicological Concern (TTC) approach and development of new TTC decision tree – 10 March 2016 
 
 30 
effects by Munro et al. (1996), which were based on analyses of the no-observed (adverse) effect 
levels (NOAELs) from repeated dose toxicity data for chemicals separated into three structural 
classes using the Cramer et al. (1978) decision scheme.  
The intent of Munro et al. (1996) was to develop a database consisting mainly of NOAELs from 
chronic toxicity studies in animals. However, in many cases, the lowest and thus most conservative 
NOAEL for a chemical came from a subchronic study. In order to group NOAELs for chemicals with  
only subchronic studies with those with chronic studies to derive the cumulative distribution of 
NOAELs, subchronic NOAELs were divided by a factor of three to approximate the most likely 
NOAEL that would be derived from a chronic study. This conversion factor was based on research 
defining the relationship between subchronic and chronic NOAELs available at the time. Based on 
an analysis of 222 NOAEL ratios of subchronic/chronic rat studies and 99 NOAEL ratios of 
subchronic/chronic mouse studies (Zarn et al. 2011) taken from publicly available mouse and rat 
feeding toxicity studies, and the EFSA (2012b) recommended a factor of 2 for extrapolating from 
subchronic to chronic study duration in rodents, which means that the factor of three used by 
Munro et al. (1996) can be considered to be conservative. A TTC value was calculated by Munro et 
al. (1996) from the respective distribution of NOAELs for each of the 3 Cramer structural classes, 
using a database of 613 chemicals with 2941 NOAELs, representing a range of industrial chemicals, 
pharmaceuticals, food chemicals and environmental, agricultural and consumer chemicals likely to 
be encountered in commerce with good supporting toxicological data, yielding 137, 28 and 448 
chemicals in Cramer class I, II and III, respectively. For each of the 613 chemicals, the most 
conservative NOAEL was selected, based on the most sensitive species, sex and endpoint. The fifth 
percentile NOAEL (in mg/kg bw/day) was calculated for each structural class and this was 
converted to the intake for a 60kg person following the application of a safety factor to calculate 
the TTC value. In converting the fifth percentile NOAELs to a TTC value for the three structural 
classes, a 100-fold safety factor was used, the default safety factor used for establishing health-
based guidance values for chemicals using toxicity data from animal studies. This procedure 
resulted in TTC values of 1800, 540, 90 μg/person/day for Cramer classes I, II and III, respectively. 
A number of criticisms of the TTC approach were raised at a workshop organised by the ILSI 
Europe TTC Task Force in 1999 (Barlow et al., 2001), principally in relation to some potentially 
sensitive endpoints: immunotoxicity, developmental toxicity, neurotoxicity and developmental 
neurotoxicity, endocrine active chemicals and allergenicity. These issues were considered, where 
possible, by analyses of databases selected for these endpoints (Kroes et al., 2000). Such selective 
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databases are considered conservative since chemicals are likely to have been selected for special 
endpoint study for some a priori reason. For developmental toxicity, the distribution of NOAELs 
divided by 100 was about 3 orders of magnitude higher than the distribution of 1 in a million 
upper-bound lifetime risk estimates derived from carcinogenicity data. Importantly, the 
cumulative distribution of NOAELs was similar to that of Class III chemicals in the Munro et al. 
(1996) database, i.e. developmental toxicity was not more sensitive than other non-cancer 
endpoints, indicating that a specific TTC was not necessary. For adult neurotoxicity, the 
distribution of NOAELs was lower by about one order of magnitude than those for other non-
cancer endpoints, including developmental neurotoxicity (Kroes et al., 2000).  
For allergies, hypersensitivity reactions and intolerances, none of the current testing strategies 
were considered adequate for such effects and, therefore, there is no database to develop TTC 
values and these endpoints are not included in the TTC approach. However, in the absence of 
suitable animal models, the TTC is not different to any of the other approaches to risk assessment.  
These analyses led to further refinements of the TTC approach: Kroes et al. (2004) developed a 
TTC value for chemicals with certain structural alerts for genotoxic carcinogenicity (0.15 μg/day, 
calculated by linear extrapolation to a theoretical upper-bound risk of one in a million from the 
TD504) and a separate TTC value for organophosphate chemicals (18 μg/day). It was acknowledged 
that organophosphate chemicals are usually regulated products and it was clearly stated that the 
TTC approach should not be considered an alternative to testing procedures required for 
regulatory approval.  
Removing organophosphate and carbamate chemicals from Cramer Class III, being the most 
potent chemicals in that class, would have an impact on the existing TTC value for Cramer Class III. 
Kroes et al. (2004) did not propose to revise the TTC value for Cramer class III and the EFSA 
(2012a) stated that, pending any future revision of the TTC approach, it would be prudent to 
maintain the value for Cramer Class III at 90 μg/person per day. On the other hand, Felter et al. 
(2009) proposed to revise the existing TTC value for Cramer Class III to 180 μg/person per day 
after removing organophosphate and carbamate chemicals from Cramer Class III. Munro et al. 
(2008) noted that exclusion of organophosphate and carbamate chemicals would give a corrected 
Class III TTC value of 180 μg/person/day instead of 90 μg/person/day and, in addition, if 
                                                      
4 The TD50 is defined as the daily dose-rate in mg/kg body weight per day for life to induce tumours in half of the test animals that would have 
remained tumours-free at zero dose.  
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organohalogen chemicals are also excluded from Cramer class III, the resulting corrected Class III 
TTC value would be about 600 μg/person/day. Kroes et al. (2004) also developed a step-wise 
decision tree which incorporates the various TTC values in decreasing order of concern and 
increasing numerical values. At the beginning, they included an exclusion category for certain 
types of chemicals that should not be assessed by a TTC approach. The reason for this was either 
that similar structures were not represented in the database and/or that established risk 
assessment approaches already exist (heavy metal and TCDD-like chemicals), or that they 
represent high potency genotoxic carcinogens (aflatoxin-like chemicals, N-nitroso-chemicals and 
azoxy-chemicals – the so-called cohort of concern (CoC)). Separate TTC values could be developed 
for the CoC, but it was considered that the resulting TTC values would to be too low to be of 
practicable use.  
The use of the TTC approach as a pragmatic risk assessment or prioritization tool has become 
established in several areas of chemical risk assessment in the regulatory context, including food 
contact materials (US FDA, 1995), food flavouring agents evaluated by the Joint FAO/WHO Expert 
Committee on Food Additives (JECFA) and the European Food Safety Authority (EFSA) (WHO, 
1997; Munro et al., 1999; Renwick, 2004) and impurities in pharmaceutical products (EMEA, 2006, 
2007; US FDA, 2008). Areas currently under consideration for the future uses of TTC include 
metabolites of plant protection products (pesticides) (Brown et al., 2009), cosmetics (Kroes et al., 
2007; SCCP, 2008) and consumer products (Blackburn et al., 2005).  
The application of the TTC approach would also permit prioritization of risk assessment resources 
(fiscal, time and human expertise) to chemicals posing potentially greater risks. Although the TTC 
approach has traditionally been used in human health assessments for oral exposures there is no 
reason why it could not be adapted for other routes of exposure including dermal (Kroes et al., 
2007; Safford, 2008) and inhalation (Carthew et al., 2009; Escher et al., 2010).  
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Aesculus hippocastanum 
 cortex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toxic 
component 
Approach Remarks 
Acceptable 
amount 
UF 
esculin 
LHRDaescin oral 
LHRDwater extract oral 
 
France “traditional use”: Traditionally used in 
the symptomatic treatment of functional 
disorders of cutaneous capillary fragility, such as 
ecchymosis, petechias, etc. Traditionally used in 
subjective signs of venous insufficiency, such as 
heavy legs. Traditionally used in haemorrhoidal 
symptoms.  
As there are no clinical studies conducted with 
horse chestnut bark in children and adolescents 
under the age of 18 years, horse chestnut bark 
should not be used in this target population and 
should be limited to adults and elderly. 
Kidney failure has been documented in children 
and adults after receiving injections of aescin, 
and in adults after taking high doses of aescin 
(Chandler 1993)  
40 mg/die 
400 mg/die  
/ 
 
 
References: 
 
• Bézanger-Beauquesne L, Pinkas M, Torck M and Trotin F. Aesculus hippocastanum L. Plantes médicinales des 
régions tempérées. Paris: Maloine, 1980, 2è ed., 164-165  
• Bombardelli E, Morazzoni P and Griffini A. Aesculus hippocastanum L. Fitoterapia 1996, 67:483–511  
• Chandler RF. Herbal medicine: horse chestnut. Can. Pharm. J., 1993, 126, 297, 300-306  
• Fournier P. Marronnier d’Inde – Aesculus hippocastanum L. Le livre des plantes médicinales et vénéneuses de 
France. Paris: P. Lechevalier Éditeur, 1948, T.2, 475-479  
• Paris M, Moyse H. Abrégé de matière médicale, Tome 1. Paris: Masson, 1981, 147-150  
• Wichtl M et al. Plantes thérapeutiques, 2è ed. Paris: Editions Tec et Doc/EM Inter, 2003, 294-296  
 
Main components 
 
The most characteristic compounds are coumarin derivatives (up to 7%):  
- Glucosides: Esculin (6-(β-D-glucopyranosyloxy)-7-hydroxy-2H-1-benzopyran-2-one, or 
6,7- dihydroxycoumarin 6-glucoside), a glucoside of esculetin (6,7-dihydroxy-2H-1-
benzopyran-2- one, or 6,7-dihydroxycoumarin),  Fraxin (8-(β-D-glucopyranosyloxy)-7-
hydroxy-6-methoxy-2H-1-benzopyran-2-one, or 7,8- dihydroxy-6-methoxycoumarin-8-β-
D-glucoside), a glucoside of fraxetin (7,8-dihydroxy-6- methoxy-2H-1-benzopyran-2-one, 
or 7,8-dihydroxy-6-methoxycoumarin); Scopolin (7-(β-D-glucopyranosyloxy)-6-methoxy-
2H-1-benzopyran-2-one), a glucoside of scopoletin (7-hydroxy-6-methoxy-2H-1-
benzopyran-2-one, or 7-hydroxy-6-methoxy- coumarin); Aglycones: esculetin, fraxetin 
and scopoletin.  
Other constituents are: tannins (up to 2 %), flavonoids, anthocyanins, catechins 
derivatives, traces of aescin.  
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Althaeae officnalis 
radix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toxic component Approach Remarks Acceptable amount UF 
/ NOEL human oral  
125 mg/Kg b.w./day 2000 
 
 
 
References: 
 
• Benbassat N, Kostova B, Nikolova I, Rachev D. Development and evaluation of novel lozenges containing 
marshmallow root extract. Pak J Pharm Sci 2013, 26(6):1103-1107 
• Deters A, Ziffel J, Hellenbrand N, Pappai D, Possemeyer C, Hensel A. Aqueous extract and polysaccharides 
from Marshmallow roots (Althaea officinalis L.): Cellular internalisation and stimulation of cell physiology of 
human epithelial cells in vitro. J Ethnopharmacology 2010, 127:62-69  
• EMA/HMPC/436680/2015 
• ESCOP Monographs 2nd ed. Althaeae radix–Marshmallow root. European Scientific Cooperative on 
Phytotherapy, editor. Thieme, Stuttgart 2003, 32-35  
• Mascolo N, Autore MG, Capasso F, Menghini A, Fasulo MP. Biological screening of Italian medical plants for 
anti-inflammatory activity. Phytother Res 1987, 1:28-31  
• Rouhi H, Ganji F. Effect of Althaea officinalis on cough associated with ACE inhibitors. Pakistan J Nutr 2007, 
6(3):256-258  
• Schmidgall J, Schnetz E, Hensel A. Evidence for bio adhesive effects of polysaccharides and polysaccharide-
containing herbs in an ex vivo bioadhesion assay on buccal membranes. Planta Med 2000, 66:48-53  
 
 
Main components 
Mucilage: polysaccharides 5-11.6  
Pectins: 11 % 
Starch: 25-35 % 
Mono-, Di-saccharides saccharose: 10 %; crude mucilages contained 5 
% glucose in spring and 20 % glucose in winter 
Flavonoids 0,14 – 0.28 % 
Phenolic acids 
Coumarins 
Other compounds: phytosterols, calcium oxalate, fat, tannins acids, 2 % 
asparagine, glycine betain  
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Angelicae sinensis 
radix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toxic component Approach Remarks Acceptable amount UF 
Safrole 
Isosafrole 
Umbrelliferone 
TTC 
There are no quantitative data on 
the content of safrole and 
isosafrol. 
 
The essential oil contains also 
safrole, described in the EFSA 
compendium on botanicals 
containing toxic substances of 
concern (2009) as a weak 
carcinogen; as well as in rats and 
mice and a known genotoxic 
carcinogen, and isosafrole, a weak 
hepatocarcinogen in rats and mice. 
0,15 µg/day / 
 
References: 
 
• Bradley RR, Cunniff PJ, Pereira BJG, Jaber BL. Hematopoietic effect of Radix angelicae sinensis in a 
hemodialysis patient. American Journal of Kidney Diseases 1999, 34:349-354  
• Chen SW, Min L, Li WJ, Kong WX, Li JF, Zhang Yj. The effects of angelica essential oil in three murine tests of 
anxiety. Pharmacology Biochemistry and Behavior 2004, 79:377-382  
• Deng S, Chen S-N, Yao P Et al. Serotonergic activity-guided phytochemical investigation of the roots of 
Angelica sinensis. J Nat Prod 2006, 69:536-541 
• EFSA. Compendium of botanicals that have been reported to contain toxic, addictive, psychotropic or other 
substances of concern. European Food Safety Authority. EFSA Journal 2009, 7:281  
• EMA/HMPC/614586/2012 
• Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at 
low levels in the diet (Kroes et. al, 2003) 
 
 
Main components 
Alkyl phthalides (ligustilide, (Z)-ligustilide, (Z)-6,7-epoxyligustilide, angelicide, (Z)-
butylidenephthalide, butylphthalide, 2,4-dihydrophthalic anhydride), which are the major 
components of the essential oil of the roots.  
Oil fraction: terpenes (β-cadinene and cis-β-ocimene).   
Aromatic compounds: phenol, o-cresol, p-cresol, guaiacol, 2,3-dimethylphenol, 
pethylphenol, m-ethylphenol, 4-ethylresorcinol, isoeugenol, carvacrol, 2,4-
dihydroxyacetophenonecadinene, safrole, isosafrole and vanillin.  
Among characteristic non-volatile constituents are phenylpropanoids ((E)-ferulic acid, 
coniferyl ferulate); benzenoids (valerophenone-o-carboxylic acid and vanillic acid) and 
coumarins (angelol G, angelicone and umbelliferone), and also 6-methoxy-7-
hydroxycoumarin (scopoletin), 6-ethoxycoumarin. 
 
Furthermore, have been found osthole and furocoumarins: bergapten (5-
methoxypsoralen, 5-MOP), imperatorin, psoralen, oxypeucedanin. 
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Arnica montana 
flos 
 
 
 
 
 
 
 
 
 
 
 
Toxic component Approach Remarks Acceptable amount UF 
helenalin 
flavonoil 
PDEoral 
Dermal use represents 99% of all preparations 
 
Genotoxicity: The mutagenic potential of an 
extract of Arnica (100 µl of extracts contain 
100 mg dried Arnica, extract not further 
specified) was determined in the AMES-test 
using S. typhimurium TA98 and TA100 (with 
and without metabolic activation). The Arnica 
extract (10-400 ml) produced a 2-4fold 
increase in the number of revertants (except 
TA100 without metabolic activation). The 
authors ascertained that the mutagenic effects 
could be ascribed to flavonols present in 
Arnica montana. 
0,000717 
mg/kg/day 
200 (NOEL) 
1200 (PDE) 
 
 
References: 
 
• CIR Expert Panel (2001) Final report on the safety assessment of Arnica montana extract and Arnica montana. 
Int J Toxicol 20 (Suppl 2):1-11 
• Göggelmann W, Schimmer O, Mutagenic activity of phytotherapeutic drugs. Prog Clin Biol Res, 1986, 
206, 63-72 
• EMA/HMPC/198794/2012 
• Alonso D et al., Effects of topical Arnica gel on post-laser treatment bruises. Dermatol Surg, 2002, 28, 686-688  
• Bergonzi MC et al., Evaluation of skin permeability of sesquiterpenees of an innovative supercritical carbon 
dioxide arnica extract by HPLC/DAD/MS. Pharmazie, 2005, 60, 36-38  
• Corazza M et al., Use of topical herbal remedies and cosmetics: a questionnaire based investigation in 
dermatology out patients. Journal compilation European Academy of Dermatology and Venerology, 2009, 
10.1111, 1468-3083  
• Spettoli E et al., Contact dermatitis caused by sesquiterpene lactones. Contact Dermatitis, 1998, 9 (1), 49-50  
 
 
 
Main components 
Sesquiterpenes: The most relevant constituents so far are helenalin and 11,13-dihydrohelenanin 
and their derivatives (0,3%-1%). 
 
More recent investigations led to the detection of methylated flavonoids (0.4 to 0.6%) and further 
sesquiterpene lactones 
 
essential oil (0.2 to 0.35%) 
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Avena sativa 
 Herba cum fructus 
 
 
Toxic 
component 
Approach Remarks 
Acceptable 
amount 
UF 
avenanthramide 
avenacoside A 
avenacoside B 
Food Approach 
 
Due the presence of saponins, of course, the 
intravenous route of administration must be excluded 
Avena sativa L. has been known for more than 4000 
years as a food and the traditional medicinal usage of 
Avena sativa has been documented since the 12th 
century  
 
3700 mg/die 
1100 mg/die 
/ 
 
References: 
 
 
• EMEA/HMPC/202967/2007  
• Hänsel R., Keller K., Rimpler H., Schneider G. Hager’s Handbuch der Pharmazeutischen Praxis. Drogen A-D. 
Springer-Verlag, Berlin 1992: 437-46.  
• Heinoven M., Ollilainen V., Linkola E., Varo P., Koivistoinen P. Carotenoids and retinoids in Finnish foods: cereal 
and bakery products. Cereal Chem. 1989; 66 (4): 270-3.  
• Karmally W., Montez MG., Palmas W. Et al. Cholesterol-lowering benefits of oat-containing cereal in Hispanic 
Americans. J. Am. Diet. Assoc. 2005; 105: 967-70.  
• Scientific Opinion on the substantiation of a health claim related to oat beta-glucan and lowering blood cholesterol 
and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006 - EFSA Journal 
2010;8(12):1885 
Main components 
Sugar fraction: mucilage (beta-glucan); 3 to 4% sugar (fructose, glucose),  
Protein fraction: contains glutelin (> 50%) and avenin. The globulin of oats fruits could be separated into an acidic (32,500 - 37,500 
Dalton) and a basic part (22,000 - 24,000 Dalton). The unreduced protein exists as disulfide-linked alpha/beta species of molecular weight 
53,000 to 58,000. There is a considerable heterogeneity within both groups of polypeptides. The protein fraction of oats contains more 
lysine as compared to other cereals. Endosperm, hulls (outer shells), embryonic axis and scutellum are rich in glutamic acid. Various 
enzymes were identified, including alpha-amylase, phosphatase, tyrosinase, maltase and lipase. From a practical point of view the lipases 
are the most important. Hydrolysis of the triglycerides is undesirable, due to the soapy and bitter flavours which can result.  
Lipid fraction: the grains of oats contain the highest lipid fraction among all feeding crops belonging to the family of the Poaceae. 
Unsaturated hydroxy fatty acids are formed by lipid peroxidase activity. Avenothionin was identified as a viscotoxin-like purothionin low 
molecular weight lipoprotein. It could be separated into alpha and beta avenothionin, of which the former had 47 amino acids.  
Alkaloids: The indole alkaloid gramine is thought to be responsible for a weak sedative effect similar to Passiflora incarnata.  
Organic acids: Diverse organic acids: malic, citric, malonic, aconitic, oxalic acid: (the latter up to 0.04%). Caffeic and ferulic acid have 
antioxidant properties. Avenanthramides are described as polyphenols in oats seeds. The latter represents a group of phenolic 
compounds which are not present in other cereal grains. Steaming and flaking of dehulled oat groats (inner kernel) resulted in moderate 
losses of avenanthramide Bp, while ferulic acid and vanillin increased. Avenanthramides Bc and Bf were not affected by steaming.  
Flavonoids: To date, 28 flavonoids have been identified in the seeds and the green parts of the plant. Rhamnosylisoswertisin may have 
phytoalexin properties, protecting the plant against mycoses. Also 3 flavonolignanes derived from the flavone, triticin, were isolated from 
Avena sativa herb. In the known compounds a coniferyl alcohol moiety is linked to the flavone by an ether bond. In a new natural 
product, it is linked by C-C bonds.  
Saponins may also protect oats against fungal infections. They are of the triterpene saponin type. 
 Steroids in the seeds like avenasterin and stigmasterin.  
Vitamins: A, B1, B6, E 
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Camelia sinensis 
folium non fermentatum 
 
 
 
 
 
Toxic component Approach Remarks Acceptable amount UF 
EGCG  
Saponins 
 
LHRD 
NOELEGCG human oral 
NOELEGCG human 
parenteral 
In vitro studies by Schmidt et al., 2005 
showed that high concentrations (100-
500 μg/ml) of green tea extracts 
(containing 47.5-52.5% polyphenols) can 
damage rat hepatocytes. In a separate 
series of experiments EGCG (at 
concentration of 200 μM) was identified 
as the cytotoxic compound, in contrast 
with EC, caffeine and theanine. The 
authors concluded that extremely high 
concentrations were required in vivo, 
taking into account the low oral 
bioavailability of catechins.  
Polyphenons (extracts with a mixture of 
catechins) have even higher LD50, 
suggesting extremely low toxicity of these 
(Hara, 2001)  
250 mg (Spain TU)5 
34,75 mg/Kg b.w./day 
4,875 mg/Kg b.w./day 
2000 
2000 
 
 
 
References: 
 
• Gruenwald J., Brendler T., Jaenike C. PDR for Herbal Medicines. 2nd ed. Montvale, NJ: Medical Economics 
Company, Inc, 2004, 408-414 
• Hara Y. Green tea- Health benefits and application, Marcel Dekker Inc, 2001, 18:178 
• Schmidt M., Schmitz H.-J., Baumgart A., Guedon D., Netsch M.I., Kreuter M.-H., Schmidlin C.B., Schrenk D. 
Toxicity of green tea extracts and their constituents in rat hepatocytes in primary culture. Food Chem Toxicol 
2005, 43:307–314  
 
 
 
                                                      
5 On the Spanish market, as “traditional use” 
Main components 
Methylxanthines: caffeine (2.5 to 4.2%), theophylline (0.02-0.04%), theobromine (0.15-0.2%)  
Flavonoids: Flavonols: quercetin, kaempferol, myricetin mainly as 3-O-glycosides Flavones: 
apigenin, luteolin as C-glucuronides  Flavanols: (flavan-3-ols 10-25%): (-)-epicatechin (EC), (-)-
epicatechin-3-O-gallate (ECG), (-)- epigallocatechin (EGC) and (-)-epigallocatechin-3-O-gallate 
(EGCG)  
Phenolic acids: including among others, chlorogenic acid, gallic acid, theogallin  
Amino acids: 19 amino acids, amongst which theanine [5-N-ethyl glutamine (3% w/w)]  
Terpene saponins (theafolia saponins): aglycones including among others, barringtogenol C, R1- 
barringenol   
Polysaccharides (13 %) Proanthocyanidins (tannins) 
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Capsella bursa-pastoris 
herba 
 
Toxic component Approach Remarks Acceptable amount UF 
sinigrin 
saponins 
NOELhuman  
NOELhuman parenteral 
Signs of toxicity were described as 
sedation, enlargement of pupils, paralysis 
of hind limbs, difficulty in respiration, and 
death by respiratory paralysis 
 
A quaternary ammonium salt has been 
isolated from the herb  
 
Analysis of herbs and their decoctums 
and tinctures by ICP-OES revealed that 
Capsella contains essential elements as 
Ca, Cu, Cr, Fe, K, Mg, Mn, Na and Zn, of 
which some in relatively high amounts 
(Ca, Cr, K and Na) compared to the other 
9 analysed plant species 
 
NOEL parenteral is calculated just as 
example. given the presence of saponins, 
the parenteral route of administration 
must be avoided 
787,5 mg/Kg b.w./day 
37,5 mg/Kg b.w./day 
2000 
2000 
 
References: 
 
• Barnes J, Anderson L, Philipson JD. Shepherd’s Purse. Herbal Medicines, 3rd edition, Pharmaceutical Press, 
London 2007, 541-542.  
• Martindale: The Complete Drug Reference. Shepherd’s Purse.S. C. Sweetman. The Pharmaceutical  
• Press 36th edition. London 2009  
• Kuroda K, Kaku T. Pharmacological and chemical studies on the alcohol extract of Capsella bursapastoris. 
Life Sciences, 1969, 8(I):151-155.  
• Szentmihalyi K, Taba G, Lado C, Fodor J, Then M, Szoke E. Medicinal plant teas recommended as 
natural source for element supplementation. Acta Alimentaria, 2005, 34(2):161-167 
Main components 
Flavonoids (a.o. flavonglycosides): quercetin, tricin, diosmetin, kaempferol, luteolin, hesperitin 
and derivated glycosides (e.g. rutin, diosmin, hesperidin, luteolin-7-rutinoside, luteolin-7- 
galactoside, quercetin-3-rutinoside). 
Amines: choline (1%), acetylcholine, histamine 
Aminoacids: (22, a.o. proline, tyramine, and ornithine), (poly)peptides (a.o. α- and γ- 
aminobutyric acid, α-aminoadipic acid) and proteins 
Aliphatic and phenolic acids: chlorogenic, vanilic, syringic, fumaric acid 
Volatile oil, with at least 74 components identified, with camphor as major constituent 
(0.02%). 
Resin 
Saponins  
Other constituents: 9-methylsulfinylnoyl and 10-methylsulfinyldecyl glucosinulates (in seeds), 
carotenoids, ascorbic acid, vitamin K, cardenolide, calcium and potassium salts, unidentified 
alkaloids, mustardoil glucoside (e.g. sinigrin, possibly responsible for the off-flavours in dairy 
products,).  
 
Young leaves contain Vitamin A (5,000 IU/100 g) and ascorbic acid (91 mg/100 g) 
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Carum carvi  
Herba cum fructus 
 
 
Toxic component Approach Remarks Acceptable amount UF 
Carvone 
NOELoil human oral 
NOELcarvone human oral 
The European Food Safety Authority 
(EFSA) Scientific Committee has published 
a safety assessment of d-carvone. In the 
assessment report, unpublished data 
from a 90-day NTP study in rats from the 
year 1982 is presented. The EFSA 
Scientific Committee concluded that 
relative liver weight of the surviving dose 
groups (93, 187 and 375 mg/kg) was 
statistically significantly increased 
compared with controls.  
For what above mentioned was not 
chosen the PDE approach for carvone but 
an UF 3000 for a restrictive approach  
167,5 mg/Kg b.w./day 
27,3 mg/Kg b.w./day 
2000 
3000 
 
 
 
References: 
 
• ESCOP Monographs 2nd ed. Carvi fructus – caraway fruit. European Scientific Cooperative on Phytotherapy, editor. 
Thieme, Stuttgart 2003, 64-69  
• NTP Toxicology and Carcinogenesis Studies of d-Carvone (CAS No. 2244-16-8) in B6C3F1 Mice (Gavage Studies). Natl 
Toxicol Program Tech Rep Ser 1990, 381:1-113  
• European Food Safety Authority (EFSA). Scientific opinion on the safety assessment of carvone, considering all 
sourse of exposure. EFSA Journal 2014, 12 (7): 3806 74pp  
• European Pharmacopoeia Online 8.2. Caraway fruit – Carvi fructus. Council of Europe. 01/2008:1080  
• European Pharmacopoeia Online 8.2. Caraway oil – Carvi aetheroleum. Council of Europe. 01/2008:1817 
 
Main components 
Caraway fruit  
Caraway fruit contains 3-7 % v/m of essential oil, consisting largely of d-carvone (50-65 %), and (+)- 
limonene (up to 45 %), with less than 1.5 % of carveol and dihydrocarveol. It also contains 10-18 % 
of fixed oil, of which the main components are petroselinic (30-43 %), linoleic (34-37 %), oleic (15-
25 %) and palmitic (4-5 %) acids. Other constituents include about 20 % of protein, about 15 % 
carbohydrates, phenolic acids, mainly caffeic acid, and traces of flavonoids such as quercetin, 
kaempferol and their glycosides. Carvenone, carvacrol and peril alcohol are found as distillation and 
storage artefacts. 
  
Caraway oil  
According to the European Pharmacopeia, caraway oil should contain 0.1-1 % β-myrcene, 30-45 % 
limonene, 50-65 % carvone and a maximum of 2.5 % of trans-dihydrocarvone and trans-carveol, 
respectively (Ph. Eur. 01/2008:1817).  
 
d-Carvone: Carvone (p-mentha-6,8-dien-2-one) is a monoterpene ketone representative of the 
terpenes 
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Centaurium erythraea  
herba 
 
 
 
 
Toxic component Approach Remarks Acceptable amount UF 
/ 
PDEhuman oral 
 
The authors stated that because of the lack 
of toxicity of the CE-extract given by the 
oral route, and relatively high NOAEL values 
for the i.p. dose in the acute study in mice, 
as well as lack of mortality or clinically 
significant adverse changes in the biological 
and haematological parameters, and the 
morphology of liver and kidneys in rats after 
90 days of daily dosing, it may be concluded 
that the CE- extract is relatively non-toxic. 
Also, in view of the doses consumed 
empirically in traditional medicine in 
Morocco, there is a wide margin of safety 
for the therapeutic use of Centaurium 
erythraea (Tahraoui et al., 2010).  
62,5 mg/Kg/day6 12000  
 
References: 
 
• Capasso F, Mascolo N, Morrica P, Ramundo E Phytotherapeutic profile of some plants used in folk medicine. Boll Soc 
Ital Biol Sper 1983, 59:1398-1404 (source: ESCOP Monograph)  
• ESCOP monographs 2nd ed. Centaurii herba - Centaury. European Scientific Cooperative on Phytotherapy, editor. 
Thieme, Stuttgart 2003, 70  
• European Pharmacopoeia 6th ed. Centaury – Centaurii herba. Council of Europe. 01/2008: 
• Kumarasamy Y, Nahar L, Sarker SD. Bioactivity of gentiopicroside from the aerial parts of Centaurium erythraea. 
Fitoterapia 2003a, 74(1-2):151-154 
• Tahraoui A, Israili ZH, Lyoussi B. Acute and sub-chronic toxicity of a lyophilized aqueous extract of Centaurium 
erythraea in rodents. J Ethnopharmacol 2010, 132(1):48-55  
                                                      
6 ethanolic extract 
Main components 
Secoiridoid glucosides are the characteristic bitter-tasting constituents, principally (75%) swertiamarin and 
smaller amounts of gentiopicroside (gentiopicrin) and sweroside (bitterness value ca. 12,000) and 
centapricin (bitterness value ca. 4,000.000). Other iridoids include bitter m-hydroxybenzoyl esters of 
sweroside, and de-acetylcentapicrin, centauroside (a dimeric secoiridoid), secologanin, 6’-m-hydroxy- 
benzoyl-loganin, dihydrocornin (a cyclopentane iridoid), gentioflavoside.  
Secoiridoid alkaloids: gentianine and gentianidin; 
Xanthones: 6 methoxylated xanthones, including eustomin (1-hydroxy-3,5,6,7,8-penta-methoxyxanthone) 
and 8-demethyl-eustomin and others;  
Organic/Phenolic acids such as p-coumaric, O-hydroxyphenylacetic, ferulic, protocatechuic, sinapic, vanillic, 
syringic, hydroxyterephthalic and 2,5-dihydroxy-terephthalic acids and oleanolic acid (0.1%); 
Phytosterols: β-sitosterol, stigmasterol, campesterol and others;  
Coumarins: 5-formyl-2,3-dihydroisocoumarin;  
Miscellaneous: flavone components and anthocyanes. 
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Centella asiatica 
herba 
 
 
 
 
 
Toxic component Approach Remarks Acceptable amount UF 
asiaticoside 
NEOLhuman oral 
LHRDasiaticoside topical 
Chronic oral administration of the 
extract to rats at 150 mg/kg for 30 
days led to no significant 
differences in body weight or 
consumption of food and water, 
nor to changes in plasma glucose, 
proteins, cholesterol or triglycerid 
levels, compared to controls. No 
macroscopic alteration in internal 
organs was evident (ESCOP 2009) 
16,875 mg/Kg b.w./day 
(70% ethanolic dry extract from 
Centella 6:1) 
12 mg7 
2000 
 
 
 
References: 
 
• ESCOP Monographs 2nd ed. Supplement 2009. Centellae asiaticae herba. European Scientific Cooperative on 
Phytotherapy, editor. Thieme, Stuttgart 2009 
• Laerum OD, Iversen OH. Reticuloses and epidermal tumors in hairless mice after topical skin applications of 
cantharidin and asiaticoside. Cancer Res 1972, 32:1463-69 
• Siddique YH, Ara G, Beg T, Faisal M, Ahmad M, Afzal M. Antigenotoxic role of Centella asiatica L. extract against 
cyproterone acetate induced genotoxic damage in cultured human lymphocytes. Toxicol In Vitro 2008, 22:10-17 
• Yen GC, Chen HY, Peng HH. Evaluation of the cytotoxicity, mutagenicity and antimutagenicity of emerging edible 
plants. Food Chem Toxicol 2001, 39:1045-53 
 
 
                                                      
7 Marketing authorization in Italy; AIC: 016222073 - 
https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000143_016222_RCP.pdf&retry=0&sys=m0b1l3 
Main components 
According to the European Pharmacopoeia the herbal substance consists of the dried, fragmented 
aerial parts, containing minimum 6% of total triterpenoid derivatives, expressed as asiaticoside 
(C48H78O19; Mr 959.15)  
 
Essential oil (0.1% of the plant): Terpene acetate, Germacrene, Caryophyllene, p-Cymol, Pinene; 
Flavone derivatives: Quercetin glycoside, Kaempferol, glycoside and in free form Astragalin; 
Sesquiterpenes: Caryophyllene, Elemene and bicycloelemene, Trans-farnesene, Ermacrene D; 
Triterpenic steroids: Stigmasterol, Sitosterol; 
Triterpenic acids: Asiatic acid, 6-hydroxy asiatic acid, Madecassic acid, Madasiatic acid, Betulinic acid, 
Thankunic acid, Isothankunic acid; 
Triterpenic acid sugar esters (= saponins or pseudosaponins) (1-8% depending on country or origin): 
Asiaticoside (major component), Asiaticoside A, Asiaticoside B, Asiaticoside A (Madecassoside) and B, 
Braminoside, Brahmoside, Brahminoside, Thankuniside, Isothankuniside; 
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Chelidonium majus  
herba 
 
 
Toxic component Approach Remarks Acceptable amount UF 
chelidonine and 
other alkaloids 
Berberine 
PDEoral 
It was found that the fresh plant can cause 
acute toxicity due to the latex. Drying of the 
plant considerably reduces the toxicity. The 
use of therapeutic doses is safe due to the 
low quantity of alkaloids in the plant 
preparations. Large doses can irritate the 
gastro-intestinal tract. An excessive use for 
long periods should be avoided because of 
the risk of hepatotoxic effects, including 
severe hepatitis, severe cholestasis and 
fibrosis. A mechanism for C. majus induced 
hepatotoxicity has not been established. In 
the literature, deadly poisonings have been 
described with children after eating the 
plant (Hänsel et al. 1992). 
 
The NOEL of Chelidonium fluid extract is the 
highest administered dose, 1820 mg/kg 
body weight/day, corresponding to 2.68 
mg/kg body weight total alkaloids.  
(Mheddhbi 2002) 
182 mg/kg/day 500 
 
 
References: 
 
• ESCOP Monographs 2nd ed. European Scientific Cooperative on Phytotherapy, editor. Thieme, Stuttgart 2003, 74-
78  
• Hänsel R, Keller K, Rimpler H, Schneider G, editors. Hagers Handbuch der Pharmazeutischen Praxis. 5th ed. 
Springer Verlag, Berlin 1992 
• Mazzanti G, Di Sotto A, Franchitto A et al. Chelidonium majus is not hepatotoxic in Wistar rats, in a 4-week feeding 
experiment. Ethnopharmacol 2009, 126: 518-24 
• Mheddhbi, S. Four-week toxicity study by oral route in rats. Weleda 2002 
• Stiborova M, Vostalova J, Zdarilova A, Ulrichova J, Hudecek J, Tschirner K, Simanel V. Macleaya cordata extract and 
Sangrovit genotoxicity assessment in vivo. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008, 152 (1): 
35-39 
 
 
Main components 
Benzylisoquinoline type (0.01-1%): with at least three subgroups: 
Benzophenanthridines: chelerythrine, chelidonine, sanguinarine, isochelidonine 
Protoberberines: berberine, coptisine, dihydrocoptisine, stylopine 
Protopine; 
Acids: chelidonic, malic, citric, caffeic (0.4%) ferulic (0.02%), p-coumaric (0.06%), gentisic and 
phydroxybenzoic acids 
Hydroxycinnamic acid derivates: (-)-2-(E)-caffeoyl-D-glyceric acid, (-)-4-(E)-caffeoyl-L-threonic acid, 
(-)-(2)-(E)-coffeoyl threonic acid lactone, (+)-(E)-caffeoyl-L-malic acid 
Others: a saponine, carotenoids, a phytocytostatin (chelidocystatin), sparteine and flavonoids. 
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Cola nitida 
semen 
 
 
Toxic component Approach Remarks Acceptable amount UF 
Cr 
dimethylamine 
food 
NOELcaffeine human oral 
The Cola nitida semen herbal 
substances/preparations are in the list 
of ingredients that may be used in food 
supplements in Italy updated on 1 April 
2009 with the following indications: 
Tonic; physical and mental tiredness. 
Stimulation of metabolism. 
 
Because caffeine and methylxanthines 
are principal components of Cola seeds, 
at least some of the potential toxicities 
could be due to them. Methylxanthine 
toxicity has been assessed extensively 
elsewhere. 
3,75 mg/Kg b.w./day 2000 
 
 
 
 
References: 
 
• Burdock GA, Carabin IG, Crincoli CM. Safety assessment of kola nut extract as a food ingredient. Food Chem Toxicol 
2009; 47: 1725-32 
• EMA/HMPC/722365/2010  
• Eteng MU, Eyong EU, Akpanyung EO, Agiang MA, Aremu CY. Recent advances in caffeine and 
theobromine toxicities: a review. Plant Foods Hum Nutr 1997; 51: 231-43 
• European Pharmacopoeia 7th ed. Colae semen. Council of Europe. 01/2008:1504 corrected 6.0 
• FDA. Listing of Food Additive. 
http://www.fda.gov/Food/FoodIngredientsPackaging/FoodAdditives/FoodAdditiveListings/ucm091048.htm 
[accessed Nov. 2011] 
• The Merck Index, 11th edition 
 
 
 
 
 
Main components 
Purine alkaloids: Cola seeds contain purine bases chiefly represented by caffeine, ranging from 1.5 to 3.2% 
(2.5% on average in the dried drug) 
Phenolic compounds: The tannin content of Cola seeds is 5-10%. Other notable constituents are the flavan-
3-ol type 
polyphenols: (+)-catechin, (-)-epicatechin, and proanthocyanidin dimers of group B, Tannins also include 
colatin, colatein, colanin . 
 Mineral contents: Ca (0.07-0.09%), Na, K (1.01-1.47%), Mg (0.2-0.27%) and Fe. Other trace elements 
determined were Zn, Co, Mn, Cu and Cr. 
Others: dimethylamine, pyrrolidine and piperidine methylamine, ethylamine, isobutylamine and 
isopentylamine, aminocids. 
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Curcuma xanthorrhiza 
 rhizoma 
 
Toxic component Approach Remarks 
Acceptable 
amount 
UF 
Essential oil foodADI curcumin 
Donatus et al. (1990) observed curcumin to be moderately 
cytotoxic in vitro, inducing slightly increased LDH-leakage from 
rat hepatocytes, accompanied by an increase in GSH-depletion.  
 
For the national toxicity programme (NTP) longterm (103-
weeks) dietary exposure studies were performed in rats and 
mice. Based on the findings in rats the NOEL for gastrointestinal 
irritation (ulcers, hyperplasia and inflammation) was established 
at 440 mg curcumin/kg/day. In mice, there were absolute and 
relative increases in liver weights after 15 months of treatment, 
with a NOEL of 220 mg/kg/day (NTP, 1993). Based on these 
results and reckoned with a safety factor of 200, the Joint 
FAO/WHO Expert Committee on Food Additives (JECFA) 
established at its 44th meeting the temporary ADI to 0–1 mg/kg 
for human, pending submission of the results of a study on 
reproductive toxicity 
0-1 mg/Kg / 
 
 
References: 
 
• Donatus AA, Sardjoko, Vermeulen NPE. Cytotoxic and cytoprotective activities of curcumin. Biochem Pharmacol 
1990, 39(12):1869-1875 
• EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS). Scientific Opinion on the reevaluation of 
curcumin (E 100) as a food additive. EFSA Journal 2010, 8(9):1679 doi: 10.2903/j.efsa.2010.1679 
• JECFA: Joint FAO/WHO Expert Committee on Food Additives, 44th meeting: WHO Food Additives Series 35: 
Curcumin. 
• Lin SC, Lin CC, Lin YH, Supriyatna S, Teng CW. Protective and therapeutic effects of Curcuma xanthorrhiza on 
hepathotoxin-induced liver damage. Am J Chin Med 1995, 23:243-254 
• National Toxicology Program (NTP). Toxicology and Carcinogenesis Studies of Turmeric Oleoresin (Cas No. 8024-
37-1) in F344/N Rats and B6C3F1 Mice (Feed Studies). Technical Report Series No. 427, NIH Publication No. 93-
3158. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, 
Research Triangle Park, NC 1993 
Main components 
Carbohydrates: 69.4% of total mass. 
Curcuminoids: this is a mixture of curcumin (diferuloylmethane), monodexmethoxycurcumin and 
bisdesmethoxycurcumin. Curcumin makes up approximately 90% of the curcuminoid content in turmeric. 
The phenolic groups in the structure of curcumin explain the ability of curcumin to eliminate oxygen-derived 
free radicals. The free radicals which can be eliminated by curcumin are hydroxyl radical, singlet oxygen, 
superoxide radical, nitrogen dioxide and NO. 
Curcumin content of the Curcuma longa rhizome varies from 0.6 to 5% of the dry mass. The dry turmeric 
rhizomes contain 3-5% curcumin, the curcumin content of turmeric oleoresin is 40%. 
Essential oil: 5.8% of total mass, constituents are: a-phellandrene 1%, sabinene 0.6%, cineol 1%, borneol 
0.5%, zingiberene 25%, and sesquiterpenes 53%. The mono- and sesquiterpenes include zingiberene, 
curcumene, α- and β-turmerone. 
Mineral matter: 3.5% of total mass. 
Moisture: 13.1% of total mass. 
Polypeptides. 
Protein: 6.3% of total mass. 
Fatty oil. 
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Eleutherococcus senticosus maxi 
 radix 
 
 
 
 
 
Toxic component Approach Remarks Acceptable amount UF 
isofraxidine 
NOAELhuman 
 from an in human study 
(6 month) 
The toxicity of Eleutherococcus 
extracts is reported to be extremely 
low. The oral acute LD50 of 
powdered Eleutherococcus in mice 
is reported to be in the range of 
about 30 g/kg 
500 mg / 
 
 
 
References: 
 
 
• EMA/HMPC/680615/2013 
• Gardner Z. and McGuffin M., 2013. Eleutherococcus senticosus (Rupr. & Maxim.) Maxim., Araliaceae. 
American Herbal Association's Botanical Safety Handbook. CRC Press. Boca Raton (Florida, US), 329-331. 
• Lee YJ, Chung HY, Kwak HK, Yoon S, 2008. The effects of A. senticosus supplementation on serum lipid profiles, 
biomarkers of oxidative stress, and lymphocyte DNA damage in postmenopausal women. Biochem Biophys Res 
Commun, 375(1):44-48. 
• Lee D, Park J, Yoon J, Kim MY, Choi HY, Kim H, 2012. Neuroprotective effects of Eleutherococcus senticosus bark on 
transient global cerebral ischemia in rats. J Ethnopharmacol, 139 (1):6-11. 
• Kuo J, Chen KW, Cheng IS, Tsai PH, Lu YJ and Lee NY, 2010. The effect of eightweeks of supplementation with 
Eleutherococcus senticosus on endurance capacity andmetabolism in human. Chin J Physiol, 53(2):105-111. 
 
Main components 
phenyl propane compounds: eleutheroside B – 0.5%, chlorogenic acid – up to 0.3% , coniferyl aldehyde and 
its glucoside, caffeic acid derivates; 
lignanes: eleutheroside E 0.1%, Eleutheroside E2, eleutheroside B4 0.023%, Eleutherosid D 0.10%, 
 Eleutherosid E1, Syringaresinol, (+)-pinoresinol di-O- β-Dglucoside;  
coumarins: isofraxidin and its O-glucoside eleutherosid B1, 7-ethylumbelliferone; 
triterpensaponines: daucosterol (eleutheroside A), β -hederin (Eleutheroside K), 2-protoprimulagenin A-
glycoside – 0.125%.  
polysaccharides: heteroglycans, eleutherans 
Other constituents: steroids, carbohydrates and essential oil 0.8% 
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Epilobium angustifolium 
 herba 
 
 
 
 
 
Toxic component Approach Remarks Acceptable amount UF 
/ 
LHRDdecotion oral 
LHRDethanolic extract 
NOELhuman 
On the market as herbal tea since 
11/04/2005 in Hungary, and as oral 
drops since 25/07/2002 (only as 
combination products therefore this 
information cannot sustain the 
safety and thus is reported as 
additional information.) 
 
herbal tea is widely distributed in 
the food sector in Poland, also in 
combination products. However, no 
further product-specific details are 
given  
 
350 mg/die 
100 mg/die 
35 mg/Kg b.w./day 
2000 
 
 
 
References: 
 
 
• EMA/HMPC/712510/2014 
• Kujawski R, Ozarowski M, Derebecka-Holysz N, Bartkowiak-Wieczorek J, Bogacz A, Karasiewicz M, et al. Effect of 
Willow herb (Epilobium angustifolium L.) extract on gene expression of selected P450 cytochromes in rat liver – 
preliminary study. Herba Pol 2009, 55(4):52-64 
• Roman A, Rusu MA, Puica C, Borsa M. Citotoxic effects of three speies of Epilobium (Onagraceae) herbal extracts in 
rats. Studia Universitatis “Vasile Goldis”, Seria Stiintele Vietii 2010, 20(1):19-23 
• Vitalone A, Bordi F, Baldazzi C, Mazzanti G, Saso L, Tita B. Anti-proliferative effect on a prostatic epitheliala cell line 
(PZ-HPV-7) by Epilobium angustifolium L. Il Farmaco 2001, 56:483-489 
 
 
Main components 
Tannins and related compounds (4-14%): e.g. oenothein B, oenothein A, tri-, tetra-, and penta-
Ogalloylglucose 
Flavonoids (1-2%): e.g. kaempferol, quercetin, myricetin.  
Phenolic acids and their derivatives: e.g. ellagic acid, valoneic acid dilactone, chlorogenic acid, 
neochlorogenic acid, coumaroylyquinic acids, feruloylquinic acids, gallic acid, cinnamic acid, protocatechuic 
acid, caffeic acid, ferulic acid. 
Steroids (ca.0.4%) and triterpenes (ca. 1.5%): e.g. cholesterol, campesterol, stigmasterol, β-sitosterol, ursolic 
acid, corosolic acid, oleanolic acid 
Other constituents: e.g. linoleic acid, palmitic acid, stearic acid, eicosenoic acid, behenic acid, arachidic 
acid 
 49 
Equisetum arvense 
 herba 
 
 
 
 
 
Toxic component Approach Remarks Acceptable amount UF 
apigenin 
 
PDEhuman oral 
 
Tago et al. (2010) evaluated the 
influence of administration of an 
aqueous extract of Equisetum 
arvense (no further information) in 
diet at doses of 0, 0.3, 1 and 3% for 
13 weeks in male and female F344 
rats (1% was thought to mirrow a 
proximate dosage level of 500 
mg/kg). No death or obvious clinical 
signs were noted in any of the 
animals. The NOAEL was determined 
to be >1.79 g/kg/day (males) and 
>1.85 g/kg/day (females) under the 
condition of the study. 
 
179 mg/Kg/die 
 
500  
(PDE on NOAEL of 
male rats) 
 
 
 
References: 
 
 
 
• Dos Santos JG Jr, Do Monte FH, Blanco MM, Lanziotti VM, Maia FD, Leal LK. Cognitive enhancement in aged rats 
after chronic administration of Equisetum arvense L. with demonstrated antioxidant properties in vitro. 
Pharmacology Biochemistry and Behaviour 2005b, 81(3):593-600 
• European Pharmacopoeia 8th ed. Equisetum Stem - Equiseti herba. 
• Joksić G, Stanković M, Novak A. Antibacterial medicinal plants Equiseti herba and Ononidis radix modulate 
micronucleus formation in human lymphocytes in vitro. Journal of Environmental Pathology, Toxicology and 
Oncology 2003, 22(1):41-48  
• Schneider K, Kubelka W. Zur Hämolytischen Wirkung von Schachtelhalmkraut (Herba Equiseti). Scientia 
Pharmaceutica 1989, 57(3):214-215  
• Tago Y, Wei M, Ishii N, Kakehashi A, Wanibuchi H. Evaluation of the subchronic toxicity of dietary administered 
Equisetum arvense in F344 rats. Journal of Toxicologic Pathology 2010, 23(4):245-251  
Main components 
Inorganic constituents: with 5-7.7% silicic acid (or silicates respectively) of witch 10% are water- soluble, 
1.5% aluminium chloride, potassium chloride and manganese   
Flavonoids: mostly kaempferol- and quercetin glycosides and their malonyl esters, luteolin-5-O-β-D- 
glucoside, apigenin-5-O-β-D-glucoside und 6-chloroapigenin; the pharmacopoeial standard is minimum 0.3% 
of total flavonoids.    
Alkaloids: small amounts of nicotine, 3-methoxypyridine, traces of palustrin are possible; equisetonin, a 
saponin-complex, i a mixture of sugars and flavonoids; Schneider & Kubelka (1989) suggested, equisetonin 
should be cancelled from the list of compounds of horsetail, as it does not exist  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Euphrasia officinalis  
herba 
 
 
 
 
 
Toxic component Approach Remarks Acceptable amount UF 
Apigenin TTC8 
From a phytopharmacological point of 
view Euphrasia may be associated with 
different effects: adstringent (due to the 
tannins) and anti-inflammatory (due to 
the iridoids). However, no studies have 
been performed. 
 
Tests on reproductive toxicity, 
genotoxicity and carcinogenicity have not 
been performed. 
 
Only one study concerning the acute 
toxicity of aqueous eyebright extract on 
six mice is in litterature. 
1800 µg/day / 
 
 
 
References: 
 
 
• British Herbal Pharmacopoeia. Scientific Committee, British Herbal Medicine Association, Bournemouth 1983, 89–
90  
• Chudnicka A, Matysik G. Research of enzymatic activities of fresh juice and water infusions from dry herbs. J 
Ethnopharmacol 2005; 99(2):281-286  
• EMA/HMPC/246799/2009 
• Porchezhian E, Ansari SH, Shreedharan NK. Antihyperglycemic activity of Euphrasia officinale leaves. 
Fitoterapia 2000; 71(5):522-526 
• Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low 
levels in the diet (Kroes et. al, 2003) 
 
 
                                                      
8 TTCs values are set under the munro's scheme because are not intended for a chronic use. 
Main components 
 
Flavonoids: 0.38% apigenin, luteolin, kaempferol, rhamnetin, quercetin 
Polyphenols: 1.47% 
Phenolic acids: caffeic acid and its ester derivatives, chlorogenic acids and coumaric acids 
Hydroxycinnamic derivatives: 1.97% 
Tannins: 0.56% 
Iridoids: aucubin 0.05% 
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Filipendula ulmaria  
herba 
 
 
 
Toxic 
component 
Approach Remarks Acceptable amount UF 
/ 
LHRDoral 
NOELhuman parenteral 
The Council of Europe categorises 
Filipendulae ulmariae herba as a 
natural source of food flavouring that 
can be added to foodstuffs in small 
quantities, with a possible limitation of 
an active principle (as yet unspecified) 
in the final product (Barnes et al., 
2007)  
 
Due to the presence of salicylates, 
Filipendula ulmaria should not be used 
in cases of hypersensitivity to 
salicylates (Wichtl, 1994). 
 
In the ESCOP Monographs (2003), it is 
stated: “Herb is used as supportive 
therapy for the common cold and to 
enhance the renal elimination of 
water.”  
200 mg9  
0,1363 mg/Kg b.w./day 
2000 
(NOEL Rabbit) 
2500 (PDE) 
 
 
References: 
 
• Barnaulov OD, Kumkov AV, Khalikova NA, Kozhina IS, Shukhobodskij BA. [Chemical composition and primary 
evaluation of the properties of preparations from Filipendula ulmaria (L.) Maxim flowers.] Rastit Resur 1977, 
13:661-669 
• ESCOP Monographs 2nd ed. Filipendulae ulmariae herba – Meadowsweet. European Scientific Cooperative on 
Phytotherapy, editor. Thieme, Stuttgart 2003, 157-161  
• European Pharmacopoeia 6th ed. Meadowsweet – Filipendulae ulmariae herba. Council of Europe. 01/2008:1868, 
2344-2345  
• Wichtl M. Herbal drugs and Phytopharmaceuticals. 1st ed. Medpharm Scientific Publishers GmbH, Stuttgart 1994, 
480-482  
Fraxinus excelsior 
                                                      
9 On the French market, as “traditional use”- powdered herbal substance 
Main components 
Salicylates are the main components of the volatile oil, mainly salicylaldehyde (up to 70%). The amount of 
salicylates, mostly present in the form of glycosides, is assumed to be less than 0.5%  
Flavonoids: from 3-4% in the flowering herb up to 6% in the fresh flowers, in particular spiraeoside 
(quercetin-4’-glucoside), also hyperoside, other quercetin and kaempferol derivatives, as kaempferol- 4’-
glucoside.  
Tannins: hydrolysable type, ranging from 1% in ethanolic extracts to 12% in aqueous extracts, predominantly 
the dimeric compound rugosin D.  
Miscellaneous: coumarin (trace), mucilage, carbohydrates, ascorbic acid.   
 52 
folium 
 
Toxic 
component 
Approach Remarks 
Acceptable 
amount 
UF 
 
LHRDhuman oral 
TTC 
 
Esculetin was proven to be of sensitising potency within the frame of 
studies performed on coumarins used in perfumery, cosmetics and 
therapeutic ointments. Esculetin, esculin and isoscoloplamine showed a 
local photosensitising effect in an animal study. 
  
Coumarin compounds detected so far in ash leaf do not possess the 
minimum structural requirements (a C-4 hydroxyl substituent and a C-3 
non-polar carbon substituent) for anticoagulant activity.  
 
Toxicological data is very limited. Due to the lack of data on acute and 
chronic toxicity, repeated dose toxicity, genotoxicity, mutagenicity, 
carcinogenicity, reproductive and developmental toxicity, the safety of 
the therapeutic application of ash leaf cannot be substantiated. 
Nonetheless, neither the chemical composition nor the long-term 
widespread use in the European Union suggests that there is any risk 
associated with the use of ash leaf products, thus the use can be 
suggested to be deepened.  
750 mg/die10 
540 µg/day 
/ 
 
References: 
• Barnes J, Anderson LA, Phillipson JD. Chamomile, Roman. In: Barnes J, Anderson LA, Phillipson JD. Herbal 
Medicines. 3rd Edition. Pharmaceutical Press, London, Chicago 2007, 157  
• Gaedcke F. Fraxinus. In: Hänsel R, Keller K, Rimpler H, Schneider G, editors. Hagers Handbuch der 
Pharmazeutischen Praxis. Drogen E-O, Vol 5. 5th ed. Springer-Verlag, Berlin, 1993, 188-200  
• Kostova I, Iossifova T. Chemical components of Fraxinus species. Fitoterapia 2007, 78:85-106  
• Masamoto Y. [Sensitization and crossreaction of simple coumarins.] Yakugaku Zasshi. 2001, 121:97- 103 [Japanese] 
• Ph. Eur. 6th ed. Ash leaf - Fraxini folium. Council of Europe. 01/2008:1600; 1222-1223 
Fucus vescicolosus 
                                                      
10 On the Spanish market, as “traditional use” - powdered leaves in capsules - since 1987 - indication: arthritis and diuretic  
Main components 
Simple coumarins: only in traces (0.01-0.05%). These compounds are represented in the herbal substance 
by: esculin, fraxin; esculetin, fraxetin; cichoriin; scopoletin, isoscopoletin.  
Iridoids: Very limited data are available on the occurrence of these compounds in the drug: 
deoxysyringoxide, hydroxynuezhenide, syringoxide; deoxysyringoxidine. 
Secoiridoids: A larger variety of these compounds were isolated: 10-hydroxyligstroside, 7-β-D-
glucopyranosyl-11- methyl-oleoside, oleoside-11-methyl-ester; oleoside-7,11-dimethyl-ester; excelsioside; 
oleuropein, ligstroside.  
Flavonoids: 1.4% rutoside (= rutin) 0.5%, the amount of these compounds can vary between 0.6-2.2%, from 
which 0.1-0.9% can be rutoside, but kaempferol-3-O-glucoside, quercetrin-3-O-glucoside, and their 
respective 3-O- rhamnoglucosides can also be found.  
Triterpenes: Data on the occurrence of these compounds are very limited: β-sitosterol, betuline, betulinic 
and ursolic acid (the latter in 0.7-2.5%).  
Simple phenolic acids 3.2%: ferulic, caffeic, p-coumaric, p-hydroxybenzoic, protocatehuic, sinapic, syringic 
and vanillic acids can be found in the drug  
Alkanes: hentriacontane, nonacosane, tetratriacontane.  
Other components: Mucilaginous 15.3% (broader interval from 9.5% to 22.2%); 2.5% of tannins (the range of 
0.6-4%).  
Minerals: potassium 1.7%. 
 
The aqueous dry extract contains approximately 5.7% phenolic components, while the aqueous-  
ethanolic (70% EtOH V/V) contains 8.8% (Gaedcke, 1993).  
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thallus 
 
 
 
Toxic 
component 
Approach Remarks Acceptable amount UF 
Phlorotannins 
Fucophlorethols 
LHRDhuman oral 
Possible contamination with heavy 
metals 
 
Phlorotannins from Fucus vesiculosus 
inhibited α-amylase and α-glucosidase 
and inhibited the accumulation of 
advanced glycation products by 
scavenging reactive carbonyls. 
 
Fucophlorethols from Fucus 
vesiculosus inhibited CYP1A and 
aromatase. 
120 mg/die11  
130 mg/die12  
 
/  
 
 
References: 
 
• Barnes J, Anderson AA, Phillipson JD. Herbal medicines. 3rd ed. Pharmaceutical Press London, Chicago 
2007, 273-275 
• British Herbal Compendium. Vol. 1. British Herbal Medicine Association, Dorset 1992, 37-39 
• EFSA. Tolerable upper intake levels of vitamins and minerals. European Food Safety Authority, 2006 135-150 
• Zaragoza MC, Lopez D, Saiz MP, Poquet M, Pérez J, Puig-Parellada P et al. Toxicity and antioxidant activity in vitro 
and in vivo of two Fucus vesiculosus extracts. J Agr Food Chem 2008, 56:7773-7780 
• Williamson E, Driver S, Baxter K. Stockley’s Herbal Medicines Interactions. 1st ed. Pharmaceutical 
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Fumaria officinalis 
                                                      
11 On the United Kingdom market, as “traditional use” - Fucus Aqueous Powdered Extract 5:1 
12 On the French market, as “traditional use”- powder of Fucus vesiculosus 
Main components 
Minerals: iodine (mostly bound in organic substances), with a minimum of 0.03 and a maximum 0.2 per cent 
of total iodine determined on the dried drug.  sodium, potassium, calcium, magnesium, iron, phosphor, 
sulphates, copper, chrome, chloride, zinc, manganese, silicon and selenium. 
Polysaccharides: laminarin. The content of alginic acid is estimated at 12%. Alginic acid is a linear polymer 
with various sequences of beta-(1-4)-Dmannuronic acid and alpha-(1-4)-L-guluronic acid residues; fucans of 
varying structure such as fucoidancomposed mainly of alpha-(1-2)-L-fructose-4-sulphate residues. 
Polyphenols: ca. 15%, composed of phloroglucinol units. Most are high in molecular weight (25% greater 
than 10,000), phlorotannins consisting of carbon-carbon or ether linked phloroglucinol units in linear chains 
with numerous side branches.  
Lipids: glycosyldiacylglycerids, phosphatidylethalolamin, phosphatidylcholin, eicosapentaeenacid (EPA), 
arachidonic acid (AA). 
Sterols: fucosterol, β-sitosterol  
Polyphenols: phlorotanin 
Pigments: fucoxanthin, zeaxanthinlutein, violaxanthin, neoxanthin, fucoxanthinol, β-carotene, squalene. 
vitamins: C, B1, B2, B3, B6, folic acid, choline, vitamin K 
Other constituents: pectin-like membrane slime, ethereal oil, phloroglucinol, mannitol, sorbitol, aminoacids, 
proteins. 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herba 
 
 
 
Toxic component Approach Remarks Acceptable amount UF 
sanguinarine 
corydamine 
LHRDhuman oral 
TTCethanolic 
The clinical experience with a 
Fumaria officinalis nebulisate (water 
extract of 4-6:1) as an 
amphocholinergic agent used in 64 
patients suffering from biliary 
disorders (dyskinesia, hepatopathy 
etc.) has been published by 
Zawodsky (1974). All patients were 
treated with 3 tablets containing 250 
mg of the extract daily, for 21 days. 
No adverse effects were noticed and 
an excellent tolerability was 
reported.  
 
(also if some human data are 
available the literature is poor, no 
representative data of LD50 is found 
so for an ethanolic extrac is 
suggested to apply this value of TTC 
to observe a restrictive approach) 
200 mg/day13 
540 µg/day 
 
/ 
 
 
References: 
 
• Bradley PR editor. British Herbal Compendium. Vol 1. Fumitory - Fumariae herba. British Herbal Medicine 
Association, Bournemouth 1992, 102-104. 
• European Pharmacopoeia 6th ed. Fumariae herba. Council of Europe. 1/2008: 1952. 
• Forgacs P, et al. Alcaloides des Papavéracées II: Composition chimique de dix-sept espèces de Fumaria. Plantes 
Med Phytother 1986, 20: 64-81.  
• Wynne PM, Vine JH, Amiet RG. Protopine alkaloids in horse urine. J Chromatogr B Analyt Technol Biomed Life Sci 
2004, 811: 85-91.  
• Zawodsky, L. Klinische Erfahrungen mit dem Amphocholeretikum Oddibil. [Clinical experience with Fumaria 
officinalis nebulisate, an amphocholinergic agent.] Wiener Medizinische Wochenschrift 1974, 124(46): 677-680.  
 
                                                      
13 On the Austrian market, as “well-established use” - Dry extract, extraction solvent water, DER 5:1, not less than 2.5 mg alkaloids calc. as 
protopine per film coated tablet. 1 film-coated tablet contains 250 mg extract 
 
Main components 
Alkaloids: (0.3-1% calculated as protopine (0.13%) 
protopines, the quantitatively predominant type, as protopine (fumarine) and cryptopine, Protoberberines: 
aurotensine, stylopine, N-methylsinactine and others, Spirobenzylisoquinolines: fumaritine, fumaricine anf 
fumariline and others. 
Benzophenanthridines such as sanguinarine and corydamine (traces),  
Indenobenzazepines: fumaritrididine and fumaritrine 
Flavonoids: principally glucosides of quercetin such as isoquercitrin, rutin, quercetin-3,7-diglucoside- 3-
arabinoglucoside 
Acids: chlorogenic and caffeic acids, also fumaric acid, caffeoylmalic acid and other aliphatic acids 
Other constituents: bitter principles, mucilage, resin and potassium salts  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Gentiana lutea 
radix 
 
 
 
 
Toxic 
component 
Approach Remarks Acceptable amount UF 
/ LHRD 
 
 
Different cases of poisoning in humans 
are described. The most cases were 
due to an adulteration or mistaken use 
of Veratrum album. 
 
 
 1200 mg/die14 
1000 mg/die15 
 
Proved to be on the 
European market for a 
period of 30 years  
 
/ 
 
 
References: 
 
• Commission E Monographs. Enzianwurzel - Gentianae radix. Bundesanzeiger 223, 1985. Translated in Blumenthal 
M., Busse W.R., Goldberg A., Gruenwald J., Hall T., Riggins W., Rister R., Klein S. The Complete German Commission 
E Monographs.  
• EMA/HMPC/578322/2008 
• ESCOP Monographs 2nd ed. Gentianae Radix – Gentian Root. European Scientific Cooperative on Phytotherapy, 
editor. Thieme, Stuttgart-New York 2003, 174-177.  
• European Pharmacopoeia. Ph. Eur. 6.0, 1380 (01/2008) 
• Leslie G.B., Salmon G. Repeated dose toxicity studies and reproductive studies on nine Bio-Strath 
herbal remedies. Swiss Med 1979, 1: 43-45.  
• Matsushima T., Araki A., Yagame O., Muramatsu M., Koyama K., Ohsawa K. et al. Mutagenicities of xanthone 
derivatives in Salmonella typhimurium TA100, TA98, TA97 and TA2637. Mutation Res 1985, 150: 141-146.  
• Wegner T. Anwendung eines Trockenextraktes aus Gentianae luteae radix bei dyspeptischem Symptomkomplex. Z 
Phytotherapie 1997, 19: 163-164.  
 
 
                                                      
14 Marketing authorization in Germany - (commonly as dry extract from Gentianae radix (4.5-5.5:1) ethanol 53% v/v)  
15 As fluid extract (1:1); ethanol 45% v/v  
Main components 
Bitter constituents (2-8%) are located mostly in the cortex of the root. The most bitter constituents belong 
to the class of secoiridoid glycosides, with gentiopicroside (also known as gentiamarine and gentiopicrine) as 
main component and a lower amount of amarogentine (0.025 – 0.4%) 
Up to 1% xanthones: gentisine, isogentisine, methylgentisine, gentiseine xanthones are also responsible for 
the yellow colour of the root.  
Carbohydrates: 30-55% carbohydrates in the dried root including monosaccharides (glucose and fructose), 
disaccharides (saccharose and gentiobiose), trisaccharide (gentianose) and polysaccharides (e.g. pectins).  
volatile oil 0.1 – 0.2%; used mainly in the liqueur-production for giving its characteristic flavour. 
Other constituents: phytosterols, triterpenes 
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Ginkgo biloba 
folium 
 
Toxic 
component 
Approach Remarks Acceptable amount UF 
alkylphenols 
LHRDhuman oral 
NOELhuman oral 
In crude ginkgo extracts a group of alkylphenols (e.g. 
ginkgolic acids, ginkgol, bilobol) has been described to 
exhibit potential contact allergenic and toxic 
properties. A maximum concentration of 
5 ppm has to be maintained to comply with the Ph. 
Eur. and to ensure safety of use for Ginkgo biloba leaf 
extracts. 
 
no chronic toxicity reported. There was no evidence of 
organ damage or impairment of hepatic and renal 
functions when EGb 761 was administered orally to 
rats and mice over a period of 27 weeks in doses 
ranging from 100 to 1,600 mg/kg. 
120 mg/die 16 
47,5 mg/Kg b.w./day 
2000 
 
References: 
 
•  Bebbington A, Kulkarni R, Roberts P. Persistent bleeding after total hip arthroplasty caused by herbal self-
medication. The Journal of Arthroplasty 2005, 20(1):125-126  
• DeFeudis FV. Ginkgo biloba extract EGb 761: from chemistry to the clinic. Ullstein Medical, Wiesbaden 1998 
• ESCOP Monographs 2nd ed. Ginkgo folium – Ginkgo leaf. European Scientific Cooperative on Phytotherapy, editor. 
Thieme, Stuttgart 2003, 178-210 
• Esposito M, Carotenuto M. Ginkgolide B complex efficacy for brief prophylaxis of migraine in school- aged children: 
an open-label study. Neurological Sciences 2011, 32(1):79-81  
• Guideline on medicinal products for the treatment of Alzheimer’s disease and other dementias from Committee 
for medicinal products for human use (CHMP). Doc. Ref. CPMP/EWP/553/95 Rev. 1. European Medicines Agency, 
London 2009  
• Leistner E, Drewke C. Ginkgo biloba and ginkgotoxin. Journal of Natural Products 2010, 73(1):86-92 
• Salvador RL. Herbal medicine - Ginkgo. Canadian Pharmaceutical Journal 1995, 39-41, 52 
• NTP technical report on the toxicology and carcinogenesis studies of Ginkgo biloba extract (CAS No. 90045-36-6) in 
F344/N rats and B6C3F1/N mice (gavage studies). National toxicology program, Research triangle park, North 
Carolina 2013  
 
                                                      
16 “well-estabilished use” on the German, Belgian and Denmark market. 
Main components 
Terpenes: Triterpenelactones (diterpenes: ginkgolides A, B, C, J (0.06-0.23%) sesquiterpene: bilobalide (up to 
0.26%)) Triterpenes (steroids, phytosterols) Carotenoids, Polyprenols (di-trans-poly-cis-octadecaprenol) 
concentration ranges from 0.04% to 2.0%, Volatile terpenes 
Flavonoids not less than 0.5%, Flavanols (catechins), Flavones (aglycones, monoglycosides and biflavones 
with a concentration of 0.4% to 1.9%) 
Flavonols (the aglycones isorhamnetin, kaempferol, quercetin and myricetin have a concentration of 0.2% to 
1.4% w/w) 
Organic acids Polyacetate derived compounds, Alkyl phenolic acids and alkyl phenols (ginkgolic acid, 
cardanols (approx. 0.1%)), Long chain hydrocarbons (waxes) 
Lipids 
Others: carbohydrates, miscellaneous organic compounds, inorganic compounds 
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Grindelia robusta  
herba 
 
 
 
Toxic component Approach Remarks Acceptable amount UF 
Essential oil TTC 
The lack of subrchronic, genotoxicity, 
carcinogenicity as well as reproductive and 
developmental toxicity studies do not allow the 
establishment of rappresentative NOEL also if 
some acute toxicity studies are available.  
 
No mortality occurred and no toxic effects were 
apparent in rats after a single oral dose of a 
Grindelia robusta dry extract (80% ethanol) at 2.5 
g/kg body weight 
 
In sensitive persons, irritation of the gastric 
mucosa might occur (ESCOP 2009) while side 
effects listed in older scientific literature include 
gastric irritation and diarrhoea (Gruenwald et al. 
2007) as well as irritation of kidney and/or 
stomach at high doses  
 
540 µg/day / 
 
 
 
References: 
 
 
• EMA/HMPC/748221/2011 
• ESCOP Monographs. 2nd ed. Grindeliae Herba monograph. European Scientific Cooperative on Phytotherapy, 
editor. Georg Thieme Verlag, Stuttgart, Supplement 2009, 131-134 
• Goetz P. Plantes médicinales d’Amérique du Nord: apport à la phytothérapie française du traitement des 
affections des voies respiratoires. Phytothérapie 2005, 1 :19-27 
• Gruenwald J, Brendler T, Jaenicke C, LaGow B, editors. PDR for Herbal Medicines. 4th ed. Thomson PDR, Montvale 
2007, 429-430  
• Pharmacopée Française - French Pharmacopoeia 10 th ed. Grindélia - Grindelia sp. 1998 
 
 
Main components 
resin (5-20% depending on the species) consisting mainly of diterpenic acids such as grindelic acid, 7-8-
epoxygrindelic acid and 17-acetoxygrindelic acid; acetylenic compounds such as matricarianol and 
marticarianol acetate 
flavonoids such as kaempferol-3-methylether and kaempferol-3,7-dimethylether and various quercetin-
methylethers and main compounds quercetin-3-methyl-ether and 6-OH-kaempferol-3,6- dimethylether 
triterpenoid saponins with grindelia sapogenin D, bayogenin and oleanolic acid as the sapogenins  
phenolic acids such as chlorogenic, p-hydrobenzoic and p-coumaric acids  
approximately 5% of tannins  
approximately 0.2% of essential oil consisting mainly of mono- and sesquiterpenes, and especially for G. 
robusta - borneol (15.2%), alpha-pinene (10.3%), trans-pinocarveol (7%), bornyl acetate (4.5%), limonene 
(4.3%) 
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Hamamelis Virginiana 
cortex, folium et ramunculus 
 
Toxic component Approach Remarks Acceptable amount UF 
safrole 
LHRDdermal human 
PDEhuman oral 
Internal use: Haemorrhoids, varicose 
veins, heavy legs 
 
External use: skin & mucous 
inflammation, minor skin injuries. 
Neurodermitis atopica, Haemorrhoids, 
Heavy legs, Bruises. 
 
The safe use of hamamelis distillates has 
been accepted by the MLWP and HMPC, 
taking into account the data in the AR 
toxicology section (II.2.3) of the 
document EMA/HMPC/114585/2008 
5350 mg17 
 
10 mg/day 
 
500 
 
 
References: 
 
 
• Bernard P, Balansard P, Balansard G, Bovis A. Valeur pharmacodynamique toniveineuse des préparations 
galéniques à base de feuilles d'hamamélis. [Venitonic pharmacodynamic value of galenic preparations with a base 
of Hamamelis leaves]. J Pharm Belg 1972, 27(4): 505-512. 
• Hamamelidis aqua (Hamamelis water). European Scientific Cooperative on Phytotherapy, Exeter 2003. In: ESCOP 
Monographs, 2nd edition, 2003. 
• Hamamelidis folium (Hamamelis leaf). European Scientific Cooperative on Phytotherapy, Exeter 2003. In: ESCOP 
Monographs, 2nd edition, 2003. 
• Hamamelis. In: WHO monographs on selected medicinal plants. WHO, Geneva 2002, 124-136. 
• Mortelmans K, Haworth S, Lawlor T, Speck W, Tainer B, Zeiger E. Salmonella Mutagenicity tests: II. Results from the 
testing of 270 Chemicals. Envir Mutagen 1986, 8(7): 1-27. 
                                                      
17 Cream, 100 g containing 5.35 g distillate (1:1,6); Distillate of fresh Hamamelis virginiana L. leaves and branches (1:1.12-2.08), distillation agent 
ethanol 6% m/m.  – Marketing authorization for the Italian market 
Main components 
Leaf 
3-10% tannins: a mixture of catechins, gallotannins, plus cyanidin and delphinidin type proanthocyanidins; 
catechins: mainly (+)-catechin, (+)-gallocatechin, (-)-epicatechin gallate, (-)-epigallocatechin gallate; 
phenolic acids: caffeic and gallic acids 
flavonoids such as kaempherol, quercetin, quercitrin, and isoquercitrin; 
0.01-0.5% volatile oil among which 40% are aliphatic alcohols, 25% carbonyl compounds, 15% aliphatic 
esters, and a maximum of 0.2% safrol; a small amount of hamamelitannin. 
 
Bark 
8-12% tannins, Cortex tannins are qualitatively similar to folium tannins, but have a higher content of 
hamamelitannin (1-7%) monogalloylhamamelose, free gallic acid, condensed catechin tannins, and small 
amount of flavonols; approximately 0.1% volatile oil with a very complex composition. The bark contains 
significantly higher levels of phenylpropanoids and sesquiterpenoids in the volatile fractions compared to 
the leaves, which contain higher amounts of monoterpenoids. The bark is richer in hydrolysable tannins and 
the leaves mainly contain condensed tannins. 
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Harpagophytum procumbens 
radix 
Toxic 
component 
Approach Remarks 
Acceptable 
amount 
UF 
phenolic 
glycosides 
harpagoside 
LHRDhuman oral 
 
 
Adulteration: Devil's claw (Harpagophytum procumbens) 
 is occasionally adulterated with harpagoside-poor primary roots or with 
other bitter plants such as Elephantorrhiza and Acanthosicyos. 
 
The medicinal use has been documented in well-known handbooks 
dating from 1976. Dosage: (3 times daily) dried tuber 0.10-0.25 g; liquid 
extract (1:1, 25% ethanol), 0.1-0.25 ml; tincture 1:5 in 25% alcohol, 0.5-1 
ml 
 
In a randomised, double-blind, placebo-controlled study, 63 patients (31 
verum group and 32 placebo), between 18-62 years old, with slight to 
moderate muscular tension or slight muscular pain of the back, shoulder 
and neck received 2x480 mg Harpagophytum dry extract (DER 4.4-5.0:1, 
extraction solvent ethanol 60% V/V) or placebo daily for 4 weeks (Göbel 
et al., 2001). The efficacy of verum treatment was clear from the clinical 
global score and patient and physician ratings. 
 
300 mg/day18  
  
 
References: 
 
• Brendler T, Gruenwald J, Ulbricht C, Basch E. Devil’s Claw (Harpagophytum procumbens DC): an evidence-based 
systematic review by the Natural Standard Research Collaboration. J Herb Pharmacother 2006, 6:89–126 
• Bruneton J. Phytothérapie. Les données de l’évaluation Ed. TEC & DOC- EM Inter, 2002, 101-107 
• ESCOP. Harpagophyti radix (Devil’s Claw root). In ESCOP Monographs. 2nd ed. Supplement 2009, 135- 147 
• Göbel H, Heize A, Ingewersen M, Niederberger U, Gerber D. Harpagophytum-Extrakt LI 174 (Teufelskralle) bei der 
behandlung unspezifischer rûckenschmerzen. Schmerz 2001, 15:10-18  
• Grigorescu EM, Ciulei I, Stanescu U.- Index Fitoterapeutic, Edit. Medicală, Bucureşti 1986, 199-200  
• WHO monographs on selected medicinal plants. Vol. 3. Radix Harpagophyti. World Health Organisation. Geneva 
2007, 182-194 
• Wichtl M. Herbal drug and Phytopharmaceuticals 3rd ed. MedPharm GmbH Scientific Publishers 2004, 271-273 
• Zimmermann W. Planzliche Bitterstoffe in der Gastroenterologie. Z Allgemeinmed 1976, 54:1178-1184 
                                                      
18 On the German market, as “well-established use” since 1976 - Dry extract of Harpagophyti radix (1.5- 2.0:1), extraction solvent ethanol 40% 
(V/V)  
Main components 
iridoid glucosides (0.5-3%), principally harpagoside, extremely bitter (0.8-3.0% in H. procumbens, 0.7-1.7% in 
H. zeyheri), together with 8-(p-coumaroyl)-harpagide (0.03-0.17% in H. procumbens, 0.61-1.84% in H. 
zeyheri) and small amount of harpagide, procumbide and their 6’-p-coumaroyl esters. The secondary tubers 
contain approximately twice as much harpagoside as the primary tubers. 
phenolic glycosides acteoside (verbascoside) and isoacteoside, and sugars (about 51%), mainly the 
tetrasaccharide stachyose (up to 46%) with smaller amount of raffinose (a trisaccharide), sucrose and 
monosaccharides are also present. 
acylated phenolic glycoside 6-acetylacteoside has been found in H. procumbens but not in H. zeyheri, so can 
be used to distinguish between the two Harpagophytum species the ratio of 8-O-p-coumaroylharpagide to 
the sum of harpagoside and 8-O-p-coumaroylharpagide is a distinguishing feature between H. procumbens 
and H. zeyheri. In H. procumbens it is below 10% while it is above 31% in H. zeyheri  
Other compounds in small amounts: triterpenes, mainly oleanolic acid, 3β-acetyloleanolic acid and ursolic 
acid 
Phytosterols: mainly β-sitosterol, stigmasterol and their glucosides 
aromatic acids: caffeic, cinnamic and chlorogenic acids 
flavonoids including kaempferol and luteolin, harpagoquinone 
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Hieracium pilosella 
Herba cum radice 
 
 
 
 
Toxic 
component 
Approach Remarks Acceptable amount UF 
umbrelliferone 
LHRDhuman oral 
 
The traditional use of the following Hieracium pilosella 
preparations is well documented, on the basis of the 
information on the availability of products in the market 
since 1986, together with the information on the use of 
such preparations, throughout a period of at least 30 
years 
 
According to Stanojević et al. (2009) the content of total 
phenolic compounds is about 240 mg gallic acid 
equivalents/g of dry extract 
140 mg/day19 
 
/ 
 
 
 
 
References: 
 
• Beaux D, Fleurentin J, Mortier F. Effect of extracts of Orthosiphon stamineus Benth, Hieracium pilosella L., 
Sambucus nigra L. and Arctostaphylos uva-ursi (L.) Spreng. in rats. Phytother Res 1999, 13(3):222-225 
• British Herbal Pharmacopoeia. Part 2. 1st ed. British Herbal Medicine Association, Exeter 1979, 141-143  
• Bruneton J. Farmacognosia: fitoquimica, plantas medicinales. 2nd ed. Acribia, Zaragoza 1998 
• Gawrońska-Grzywacz M, Krzaczek T. Identification and determination of triterpenoids in Hieracium pilosella L. J 
Sep Sci 2007, 30(5):746-750 
• Stanojević L, Stanković M, Nikolić V, Nikoli L, Ristić D, Canadanovic-Brunet J, et al. Antioxidant Activity and total 
Phenolic and Flavonoid Contents of Hieracium pilosella L. extracts. Sensors (Basel) 2009, 9(7):5702-5714 
• Van Hellemont J. Compendium de Phytothérapie. 1st ed. Association Pharmaceutique Belge, Brussels 1986  
• Wren RC. Potter’s New Cyclopedia of Botanical Drugs and Preparations. The C.W. Daniel Company Limited, Safron 
Walden, Essex 1998  
 
 
 
                                                      
19 On the spanish market as “traditionl use” - powdered dried herbal substance 
Main components 
Hydroxycoumarins: umbelliferone (mainly as 7-glucoside; about 0.60% of the dry plant material), skimmine 
Flavonoids: luteolin, luteolin-7-O-glucoside, apigenin-7-O-glucoside (about 0.25% of the dry plant material), 
isoetin 4’-O-β-D-glucopyranoside  
Tannins 
Triterpenoids: alpha- and beta-amyrin, taraxerol, taraxasterol and fern-7-en-3-beta-ol  
Organic acids: caffeic acid, chlorogenic acid (about 20% of the dry plant material) 
Ascorbic acid  
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Hypericum perforatum 
herba 
 
 
Toxic component Approach Remarks Acceptable amount UF 
α-pinene LHRD 
Although there are no controlled studies 
with children and adolescents published it 
can be concluded that there is a 
widespread documented use of 
Hypericum extracts among adolescents. 
However, there are no data available on 
the efficacy and safety in this population. 
Therefore, the use in children and 
adolescents below 18 years of age is not 
recommended.  
 
The absorbance spectrum of the 
Hypericum extract revealed maxima in 
the whole UV 
 
600 mg/day20 / 
 
 
References: 
 
• Bernd, A., Simon, S., Ramirez Bosca, A., Kippenberger, S., Diaz Alperi, J., Miquel, J., Villalba Garcia, J.F., Pamies 
Mira, D., Kaufmann R., Phototoxic effects of Hypericum extract in cultures of human keratinocytes compared with 
those of psoralen. Photochem Photobiol. 69, 218-221. 1999 
• ESCOP Monograph. HYPERICI HERBA (St. John’s Wort). ESCOP Monographs Second edition. ESCOP 2003 
• Greeson, J.M., Sanford, B., Monti, D.A. St. John's wort (Hypericum perforatum): a review of the current 
pharmacological, toxicological, and clinical literature. Psychopharmacology. 153, 402-414. 2001 
• Leuschner, J. Preclinical toxicological profile of Hypericum extract LI 160. Abstracts of the 2nd International 
Conference on Phytomedicine, Munich. SL 80, 1996 
• Okpanyi, S.N., Lizba, H., Scholl, B.C., Miltenburger, H.G. Genotoxicity of a standardized Hypericum extract. 
Arzneimittelforschung. 40, 851-855. 1990 
 
                                                      
20 Marketing authorization in Italy - NERVAXON AIC: 033894078 
Main components 
Phloroglucinol derivates: 0.2-4%, depending on the age of the herbal drug, mainly hyperforin and 
its homologue adhyperforin, furanohyperforin 
Naphtodianthrones: 0.06-0.4%, mainly pseudohypericin and hypericin, protohypericin, 
protopseudohypericin, cyclopseudohypericin, skyrinderivatives. The amount of pseudohypericin is 
about 2-4 times higher than that of hypericin. 
Flavonoids: 2-4%, mainly glycosides of the flavonol quercetin: hyperoside, rutin, isoquercitrin, 
quercitrin; also biflavones (I3, II8-Biapigenin, Amentoflavone) 
Procyanidines: e.g. procyanidine B2, tannins with catechin skeletal (6-15%) 
Xanthones: in trace amounts 
Essential oil: 0.1-0.25%; the essential oil of dried flowering tops contains as main compounds 
2-methyloctane (16%) and α-pinene (10.6%). In the essential oil of leaves of Indian origin 58 
components were identified, α-pinene (67%) being dominant; the other components included 
caryophyllene, geranyl acetate and nonane (each about 5%) 
Other constituents: include small amounts of chloregenic acid and other caffeoylquinic and p-
coumaroylquinic acids, and also free amino acids 
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Juglans regia 
folium 
 
Toxic 
component 
Approach Remarks 
Acceptable 
amount 
UF 
Juglone 
α-pinene 
LHRD 
PDEjuglone 
The pharmacokinetics of 3H-juglone (0.02 mg/kg, i.v.) were 
studied by Aithal et al. (2011) in C57/BL mice. After the bolus 
dose about 35% of juglone accumulated within 15 min in the 
kidneys, with a half-life of about 2 h. 
 
Juglone induced cell death by apoptosis and necrosis through 
diverse mechanisms such as induction of oxidative stress, cell 
membrane damage and clastogenic effects. 
 
Cytotoxic activity of juglone was demonstrated after 72 h of 
incubation against leukemia (HL-60), melanoma (MDA-MB435), 
brain (SF-295) and colon (HCT-8) human cancer cell lines and 
against peripheral blood mononuclear cells (PMBC) as the 
control normal cell lines. The cytotoxicity of all compounds was 
tested using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT). Juglone was dissolved in DMSO 1% 
and was added to each well and incubated for 72 h. 
680 mg21 
0,014 mg/day 
200 (NOEL) 
5000 (PDE) 
 
References: 
 
• Aithal BK, Sunil Kumar MR, Rao BN, Upadhya R, Prabhu V, Shavi G, Arumugam K, Sajankila SP, Udupa N, 
Satyamoorthy K, Satish Rao BS. Evaluation of pharmacokinetic, biodistribution, pharmacodynamic, and toxicity 
profile of free juglone and its sterically stabilized liposomes. J Pharm Sci 2011, 100:3517- 3528. 
• Edenharder R and Tang X. Inhibition of the mutagenicity of 2-nitrofluorene, 3-nitrofluoranthene and 1- nitropyrene 
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• Babula P, Adam V, Havel L, Kizek R. Noteworthy Secondary Metabolites Naphthoquinones – their Occurrence, 
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• Li ZB, Wang JY, Jiang B, Zhang XL, An LJ, Bao YM. Benzobijuglone, a novel cytotoxic compound from Juglans 
mandshurica, induced apoptosis in HeLa cervical cancer cells. Phytomedicine 2007, 14:846- 852. 
 
                                                      
21 On the Hungarian market, as “traditional use” only available in combination products therefore this information cannot sustain the safety and 
thus is reported as additional information. 
Main components 
10% tannins of the ellagitannins type. not less than 2%, calculated as pyrogallol. 
Naphtalene derivatives: The most known naphthoquinone constituent is juglone (5-hydroxy-1,4-
naphtoquinone) which occurs in fresh plant (leaf, stain) as glycoside of reduced form: 4β-D-
glucoside of α-hydrojuglone=4β-D-glucoside of 1,4,5-trihydroxynaphthalene (2% in the stain, 0.6% 
in the leaves), but also in free state, particularly in the epicuticular leaf wax (to about 30%) 
Phenolic acids/phenolic composition: p-hydroxybenzoic, vanillic, genistic, protocatechuic, p-
coumaric, caffeic, ferulic, gallic, chlorogenic (3-caffeoylquinic) acids (Łuczak et al. 1989) and 
neochlorogenic (5-caffeoylquinic acid). Additionally, the presence of neochlorogenic and p-
coumaric acids in the analysed cultivars were detected; all samples exhibited the same phenolics 
profile, whereas 3-caffeoylquinic acid was the major constituent (about 19.7%) and p-coumaric acid 
was the minor compound, representing ca. 1.4% of total phenolics. 
Volatile oil: about 4 ppm, with monoterpene and sesquiterpene hydrocarbons. Monoterpenes are 
represented by: (E)-β- ocimene (12%), β-pinene (11%), limonene (10%), with traces of sabinene, α-
pinene, myrcene, and linalool, whereas sesquiterpenes by caryophyllene (15%), germacrene D 
(13%), with minor amounts of (E)-β-farnesene and α-farnesene 
Other compounds: Ascorbic acid (0.85-1%), cyclitols (11.2%), mucilage (7.6%), calcium (1.9%), 
potassium (1.4%) 
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Juniperus communis, 
pseudo-fructus  
 
 
Toxic 
component 
Approach Remarks 
Acceptable 
amount 
UF 
essential oil 
(unidentified 
compounds) 
α-pinene 
PDEoral 
PDEoral 
The dried herbal substance is used in a dose of 2 g with a 
maximum dose equivalent to 10 g per day. According to 
some authors, this posology corresponds with 
respectively 20 and 100 mg essential oil (Hänsel et al. 
1993; Barnes et al. 2007; Ph. Eur. 2008) 
 
The therapeutic indications do not relate to life 
threatening conditions and they are supported by 
traditional use evidence. There are more potent 
conventional medicines with known benefits based on 
well-established use. Groups at risk can be defined as 
constitutional: elderly, pregnant and breastfeeding 
mothers and children 
250 mg/day 
(standardised 80% 
ethanolic extract of 
Juniper pseudo- 
fructus) 
 
300 mg/day 
(lyophilized water 
extract of Juniper 
pseudo-fructus) 
500  
500 
 
 
 
References: 
 
• Barnes J, Anderson LA, Phillipson JD. Herbal Medicines, 3rd ed. Pharmaceutical Press, London 2007; 386-388. 
• British Herbal Pharmacopoeia. 4th ed. British Herbal Medicine Association, Exeter 1996; 117-118 
• De Smet PAGM, Keller K, Hänsel R, Chandler RF. Adverse Effects of Herbal Drugs Vol. 2. Springer-Verlag, Berlin / 
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editor. Thieme Verlag, Stuttgart 2003; 282-285. 
• Hänsel R, Keller K, Rimpler H, G. Schneider. Hagers Handbuch der Pharmazeutischen Praxis. Drogen E- O, Springer 
Verlag, Berlin 1993; 561-579. 
• Weiss RF, Fintelmann V. Lehrbuch der Phytotherapie. 9th ed. Hippokrates Verlag, Stuttgart 1999; 253- 255. 
 
 
 
Main components 
Monoterpenes (about 58% of the essential oil); the essential oil contains mainly α-pinene (20%), 
limonene (8.7%), myrcene (8.5%) and β-pinene, myrcene, sabinene, 1,4-cineol, camphene, Δ3-
carene, terpinen-4-ol, terpinolene, 4-terpineol, β-elemene-7-ol 
Sesquiterpenes: cadinene, α-cadinene, β-cadinene  
Diterpenic acids: isocommunic acid; labdane diterpenes 
C12 terpenoid: geijerone 
Tannins: proanthocyanidines (condensed), gallocatechin and epigallocatechin 
Flavonoids: amentoflavone, quercitin, isoquercitrin, apigenin and various glucosides 
Invert sugar (30%); glucose + fructose (about 30%) and pectin 
Organic acids: malic acid, ascorbic acid, glucuronic acid 
Lignan: desoxypodophyllotoxin 
Cerin 
Resins 
The cone berries may not contain less than 10 ml/kg of essential oil. The amount of essential oil can 
be up to 3%. The essential oil of Juniper cone berries contains about 105 constituents 
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Juniperus communis, 
oil  
 
 
Toxic 
component 
Approach Remarks 
Acceptable 
amount 
UF 
essential oil 
(unidentified 
compounds) 
α-pinene 
TTC 
There is a lot of discussion about the safe use of the oil of 
Juniperus. Some sources refer to the hyperemic effect of 
terpenes in the essential oil fraction to explain the diuretic 
action. Their action should be based on hyperemia of the 
glomeruli which is considered as an irritative action. 
Experimental pharmacological and toxicological data will be 
important in a constructive therapeutic approach. 
 
The indication for external use (promoting blood circulation in 
the skin) can be questioned as being too close to a health claim 
for cosmetics but no medicinal indication. 
 
The effect of Juniper oil (Juniper species not stated) on the 
cardiovascular and respiratory system was evaluated using 20 
rabbits, anesthetized with urethane. When Juniper oil was 
administered intramuscularly as well as orally (concentrations 
0.5%, 2.5% and 5% in corn oil: dose 1 mg/kg) a prolonged and 
slowly developing hypotonia occurred. 
540 
µg/day 
/ 
 
 
References: 
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J Serb Chem Soc 2007, 72:311-320.  
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Verlag, Berlin 1993; 561-579. 
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Main components 
α-pinene (24.1-55.4%) (range Ph. Eur. 2008 = 20-50%), β-pinene (2.1-6.0%) (range Ph. Eur. 2008 = 
1.0-12%), β-myrcene (7.3-22.0%) (range Ph. Eur.2008 = 1.0-35%), sabinene (1.4-28.8%) (range Ph. 
Eur. 2008 = less than 20%), terpinene-4-ol (0.7-17.0%) (range Ph. Eur. 2008 = 0.5-10%), α-terpineol 
(up to 1.7%), α-thujene (0.6-1.9%), caryophyllene (1.3-2.3%) (Ph.Eur. 2008 for β–caryophyllene = 
less than 7.0%), γ-muurolen (7.6%), humulen (2.1%), α-muurolen (1.1%), β-elemen (1%), β-farnesen 
(0.9%), α-cubeben (0.9%), 4-thujanol (0.8%), α-cadinol (0.8%), γ-cadinen (0.7%), aromadendren 
(0.6%), α-copaen (0.4%), bornylacetate (0.4 %) (range Ph.Eur. less than 2.0%), camphen (0.3%), 
campholenaldehyd (0.2%), p-cymene (0.2%), verbenon (0.2%). Additionally, the Ph.Eur. limits the 
concentration of α–phellandrene to less than 1.0% 
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Lavandula angustifolia, 
flos 
 
Toxic 
component 
Approach Remarks 
Acceptable 
amount 
UF 
umbrelliferone NOELhuman oral 
Toxicity of lavender oil is not a major concern. Some 
components like linalool and linalyl acetate are not 
mutagenic. The essential oil did not demonstrate 
mutagenic activity towards two strains of Salmonella 
typhimurium and one of Escherichia coli with and 
without metabolic activation. The number of strains 
used for testing and the procedure used are not 
according to the recent regulatory guidelines. A 
Community list entry cannot be established for 
Lavandula. 
 
Lavender flowers were used for investigating a 
diuretic action. Experimental pharmacological data 
point to an activity in the central nervous system: 
anticonvulsive effects, sleep prolongation, locomotor 
activity, explorative or anticonflict behaviour and 
anxiety. Well known inflammatory and nociceptive 
experimental models were used 
55 mg/Kg b.w./day 2000 
 
References: 
 
• Bickers D, Calow P, Greim h, Hanifin JM, Rogers AE, Saurat JH, Sipes IG, Smith RL, Tagami H. A toxicological and 
dermatological assessment of linalool and related esters when used as fragrance ingredients. Food and Chemical 
Toxicology 2003; 41: 919-942 
• Bruneton J. Pharmacognosie: Phytochimie Plantes Médicinales. Ed. Tec & Doc, Paris 1999; 529-530  
• Buchbauer G, Jäger W, Jirovetz L, Limberger J, Dietrich H. Therapeutic properties of essential oils and fragrances. 
In: Teranishi R, Buttery RG, Sugisama H, editors. Bioactive Volatile Compounds from Plants. AC Symposium Series 
525. Washington DC: American Chemical Society, 1993b 
• ESCOP Monographs 2nd ed. Lavandulae Flos, Lavandulae Aetheroleum. European Scientific Cooperative on 
Phytotherapy, editor. Supplement 2009. Georg Thieme Verlag, Stuttgart 2009; 147-156 
• European Pharmacopoeia 6.0 (2008a) Lavender flower oil. Council of Europe. 1/2008: 1534 
• Hänsel R, Keller K, Rimpler H, Schneider G. Hager’s Handbuch der Pharmazeutischen Praxis. Spinger Verlag, Berlin 
1993; 630-644 
Main components 
Essential oil (1-3%) 
Coumarin derivatives: umbelliferon, herniarine 
Flavonoids 
Sterols (traces): cholesterol, campesterol, stigamsterol, β-sitosterol 
Triterpenes (traces): mictomeric acid, ursolic acid 
Tannins: up to 13% in the herbal substance 
Phenylcarboxylic acids such as rosmarinic acid, ferulic acid, isoferulic acid, α-cumaric acid, p-
cumaric acid, gentisinic acid, p-OH-benzoic acid, caffeic acid, melilotic acid, sinapinic acid, sytingic 
acid, vanillinic acid. 
 
Lavender oil 
The main components of the essential oil are monoterpene alcohols (60-65%) such as linalool (20- 
50% of the fraction), linalyl acetate (25-46% of the fraction). Others include cis-ocimen (3-7%), 
terpinene-4-ol (3-5%), limonene, cineole, camphor, lavandulyl acetate, lavandulol and α-terpineol, 
β- caryophyllene, geraniol, α-pinen. Non-terpenoid aliphatic components: 3-octanon, 1-octen-3-ol, 
1- octen-3-ylacetate, 3-octanol 
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Melaleuca alternifolia 
Tea Tree Oil (TTO) 
 
 
 
 
 
 
Toxic 
component 
Approach Remarks 
Acceptable 
amount 
UF 
α-terpinene 
PDEoral 
NOAELα-terpinene 
Several reports of oral toxicity can be found in the 
literature. Data indicate that due to its systemic 
toxicity, TTO should only be used as a topical agent. 
 
Based on the available information on repeated dose 
systemic toxicity of TTO constituents, the SCCP opinion 
estimated a derived NOAEL for TTO of 117 mg /kg/day 
for renal effects (SCCP 2008, Norwegian Food Safety 
Authority) 
11,7 mg/Kg/day 
60 mg/Kg/day 
500 
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products. Cedex, France: Council of Europe Publishing 2001 
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Chem Toxicol 2006, 44(5):616-625 
• Martindale. The extra pharmacopeia. 30th ed. Melaleuca Oil. The Pharmaceutical Press, London 1993, 1385 
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Plants, Volume 2, Geneva 2004  
 
 
 
Main components 
The oil contains 42.35% terpinen-4-ol, 20.65% γ-terpinene, 9.76% α-terpinene, 3.71% terpinolene, 
3.57% 1,8-cineole, 3.09%, α-terpineol, 2.82% p-cimene, 2.42% α-pinene, 1.75% limonene, 1.05% δ- 
cadinene, 0.94% α-thujene, 0.94% aromadendrene, 0.87% myrcene, 0.73% β-pinene, 0.40% 
sabinene, and 0.34% α-phellandrene 
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Mentha piperita 
folium 
 
 
 
Toxic 
component 
Approach Remarks Acceptable amount UF 
α-Pinene 
Menthone 
Carvone 
Pulegone 
Menthofuran 
PDEdry leaves extract oral 
NOELpulegone oral 
NOELmenthone oral 
NOELcarvone human oral 
About 75% of the polyphenolic compounds 
present in the leaves are extracted in an 
infusion (Mackay, Blumberg 2006). 
 
An infusion of dried leaves is reported to 
contain 21% of the original oil (25mg/L) 
(Duband et al, 1992). 
 
Maximum levels for pulegone in foodstuff 
and beverages to which flavourings or other 
food ingredients with flavouring properties 
have been added: 25 mg/kg in foodstuff, 100 
mg/kg in beverages, with the exception of 
250 mg/kg in peppermint or mint flavoured 
beverages and 350 mg/kg in mint 
confectionery (Annex II of Directive 
88/388/EEC). 
166,67 mg/day 
20 mg/kg bw/day 
200 mg/kg bw/day 
27,3 20mg/kg bw/day 
1200 
(pde oral) 
3000 
(carvone) 
 
 
References: 
 
• Akdogan M, Ozguner M, Kocat A, Oncu M, Cicek E., Effects of peppermint teas on plasma testosterone, 
folliclestimulating hormone and luteinizing hormone levels and testicular tissues in rats. Urology, 2004c, 64:394-
398. 
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absorption in rats. Toxicol. Health, 2004a, 20:119-122 
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Mentha piperitae L., and Mentha spicata L., on kidney tissue in rats. Hum Exp Toxicol 2003, 22: 213-219. 
• Duband F, Carnat AP, Carnat A, PetitJean-Freytet C, Clair G, Lamaison JL. Composition aromatique et 
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• EMEA/HMPC/138386/2005 
• Evaluation of certain food additives. Fifty-first report of the Joint FAO/WHO Expert Committee on the Food 
Additives; WHO Geneve 2000. 
• Mohammad Jamal Saharkhiz, Marjan Motamedi, Kamiar Zomorodian, Keyvan Pakshir, Ramin Miri, and Kimia 
Hemyari Chemical Composition, Antifungal and Antibiofilm Activities of the Essential Oil of Mentha piperita L., doi: 
10.5402/2012/718645 
Main components 
The leaves contain 1.2 – 3.9% Essential oil: 
α-Pinene (0.32%), Sabinene (0.26%), β-pinene (0.58%), 1,8 Cineole (6.69%), cis-Sabinene hydrate  
(0.50%), Menthone (2.45%), Menthofuran  (11.18%), Neomenthol  (2.79%), Menthol (53.28%), 
Neomenthyl acetate (0.65%), Menthyl acetate (15.10%), Isomenthyl acetate (0.61%), β-Bourbonene 
(0.37%), (z)-Caryophyllene  (2.06%), E-β-farnesene (0.30%), Germacrene (2.01%), carvone (up to 
1%) 
Bicyclogermacrene (0.22%), pulegone (until 4%). 
 
flavonoids including luteolin and its 7-glycoside, rutin, hesperidin, eriocitrin and highly oxygenated 
flavones. Other constituents include phenolic acids and small amounts of triterpenes. Eriocitrin, 
with a concentration range of 6.6-15.0%, is the dominant flavonoid glycoside, accompanied by 
luteolin 7-0-rutinoside, hesperidin and rosmarinic acid. 
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Myroxylon balsamum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toxic component Approach Remarks Acceptable amount UF 
/ NOELhuman oral 
In a report from Germany, 59334 patients 
were tested for contact allergy to Peru 
balsam (25 % in petrolatum) between 
1996 and 2002. The result for positive 
reaction varied from 7.3 % to 11.5 % 
(Schnuch et al., 2004). 
100 mg/Kg b.w./day 2000  
 
 
 
 
References: 
 
• EMA/HMPC/712650/2014 
• Martindale. The Extra Pharmacopoeia. 30th ed. The Pharmaceutical Press, London 1993, 1401 
• Nardelli A, Carbonez A, Ottoy W, Drieghe J, Goossens A. Frequency of and trends in fragrance allergy over a 
15-year period. Contact Dermatitis 2008, 58(3): 134-141  
• Opdyke DLJ. Peru balsam. Food Cosmet Toxicol 1974, 12: 951-952 
• Schnuch A, Lessmann H, Geier J, Frosch PJ, Uter W. Contact allergy to fragrances: frequencies of sensitization 
from 1996 to 2002. Results of the IVDK. Contact Dermatitis 2004, 50(2): 65-76 
 
 
Main components 
esters of cinnamic and benzoic acids, especially benzyl cinnamate (cinnamein), cinnamyl cinnamate 
(styracine) and benzyl benzoate. Small amounts of vanillin and free cinnamic acid are also present 
(55-66 %). 
 
high-boiling volatile oil called cinnamein (50-64%), along with 20-28 % of resin. The volatile oil 
consists mainly of benzoic and cinnamic acid esters such as benzyl benzoate, 
benzyl cinnamate and cinnamyl cinnamate (styracine), with small amounts of nerolidol, free benzyl 
alcohol, and free benzoic and cinnamic acids also present. In addition, traces of styrene, vanillin, 
and 
coumarin have been identified in the material. 
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Oenothera biennis 
oleum 
 
 
 
 
 
Toxic 
component 
Approach Remarks Acceptable amount UF 
/ 
PDEoral 
LHRDoral 
Patients with atopic eczema and 
premenstrual syndrome have a deficit in 
D6D, the enzyme that converts linoleic 
acid in γ-linolenic acid. Oenothera oil 
contains γ-linolenic acid. Based on this 
biochemistry, its therapeutic use can be 
hypothesised in patients with atopic 
eczema and PMS with a D6D deficit. 
 
For the treatment and symptomatic 
relief of neurodermatitis, especially of 
the associated pruritus. 
 
12 ml/day 
50022 mg  
20 (PDE) 
 
 
References: 
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• Everett DJ, Greenough RJ, Perry CJ, et al. Chronic toxicity studies of Efamol evening primrose oil in rats and dogs. 
Med Sci Res 1988a; 16: 863-864 
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1988b; 16: 865-866 
• Hänsel R, Keller K, Rimpler H, Scheidner G. Hagers Handbuch der pharmazeutischer Praxis, Springer- Verlag, Berlin 
1993, 929-936 
• Kerscher MJ, Korting HC. Treatment of atopic eczema with evening primrose oil: rationale and clinical results. Clin 
Investig 1992; 70: 167-171 
• Riaz A, Khan RA, Ahmed SP. Assessment of anticoagulant effect of evening primrose oil. Pak J Pharm Sci 2009; 
22(4): 355-9 
 
                                                      
22 Marketing authorization in Germany - 500 mg oil per capsule - Soft capsules since 1990 
 
 
Main components 
 
at least 65% (cis)linoleic acid, 7-14% (cis)gamma-linolenic acid (γ- linolenic acid) and a maximum of 
0.5% is alpha-linolenic acid. Other substances are 5-12% oleic acid, 1-4% stearic acid, 4-10% palmitic 
acid and a maximum of 0.3% saturated fatty acids of chain length less than C16. 
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Ononis spinosa 
radix 
 
Toxic 
component 
Approach Remarks Acceptable amount UF 
Saponins 
 
LHRDtea infusion 
LHRDoromucosal 
PDEoral ethanolic extract 
Extracts of Restharrow (Ononis spinosa) 
roots in combination products are present 
on the market more than 
30 years (e.g. since 1951 in Italy) 
100 g of oral solution contain: 
Ononis spinosa radix liquid extract (DER 1:1, 
extraction solvent ethanol about 23% - 
formomonethin content 0.02%) 0.0104 g 
 
Without any further specification it is 
mentioned that Restharrow root should not 
be used in the presence of accumulation of 
water (oedema) due to impaired cardiac or 
renal function and dehydration [Blumenthal 
et al. 1998] 
2000 mg23  
10,4 mg24 
8,332 mg/day  
12000 (PDE) 
 
References: 
 
• Blumenthal M, Busse WR, Goldberg A, Gruenwald J, et al., editors. The Complete German Commission E 
Monographs. American Botanical Council, Austin Texas 1998, 213  
• Bolle P, Faccendini P, Bello U, Panzironi C, Tita B. Ononis spinosa L. Pharmacological effect of ethanol extract. 
Phamacol Res 1993, Vol. 27, (suppl 1):27-28 
• ESCOP Monographs 2nd ed. Ononidis radix - Restharrow root. European Scientific Cooperative on Phytotherapy, 
editor. Thieme, Stuttgart 2003, 351-353 
• European Pharmacopoeia 7.0. Restharrow root – Ononidis radix. Directorate for the Quality of Medicines & 
Healthcare of the Council of Europe 2010, 01/2008:1879 
• Joksić G, Stanković M, Novak A. Antibacterial medicinal plants Equiseti herba and Ononidis radix modulate 
micronucleus formation in human lymphocytes in vitro. J Environ Pathol Toxicol Oncol 2003, 22:41-4 
• Wichtl M. Herbal drugs and Phytopharmaceuticals. 3rd ed. Medpharm Scientific Publishers GmbH, Stuttgart 2004, 421-
423Evaluation of certain food additives.  
                                                      
23 (ESCOP 2003) 
24 On the italian market as “well- established use” Ononis spinosa radix liquid extracts (DER 1:1, extraction solvent ethanol about 23%: only as 
combination products therefore this information cannot sustain the safety and thus is reported as additional information. 
Main components 
 
Isoflavones: formononetin (aglycone), ononin (formononetin 7-O-glucoside), pseudobaptigenin glucoside, genistein (1.7 – 3.8 
mg/100g herbal substance), biochanin A 7-O-glucoside, biochanin A 7- O-glucoside 6”-malonate (biochanin A 0.08 – 0.70 
mg/100g), formononetin 7-O-glucoside 6”-malonate (3.2 – 5.9 mg/100g), 2.3-dihydro-ononin and also tectoridin, trifolirhizin, 
rothinidin.  
Glucosides: Spinonin, a glucoside with unusual structure has been detected, as well as medicarpin, a pterocarpan derivative.  
Triterpenes include particularly α-onocerin (4.1 mg/1g herbal substance), also known as onocol. 
Sterols: mainly β-sitosterol, stigmasterol, campesterol, cholesterol, α-spinasterol. 
Saponins: triterpenoid saponin (e.g. 3-O-[α-L-rhamnopyranosyl-(1→2)-β -D-xylopyranosyl-(1→2)- β - D-glucuronopyranosyl]-3β 
,22α-dihydroxyolean-13-en-11). 
Phenolic acids: p-hydroxybenzoic, vanillic acid, caffeic acid, syringic acid, p-coumaric acid, cinnamic acid, sinapin acid, salicylic 
acid, gentisin acid etc. can be detected in the Ononis spinosa L., radix. 
Lectins: Index Nomenclature LECp.Ono.Spi.ro.Hga1  
Small amounts of essential oil (0.02- 0.2%) are found, containing trans-anethole as the major constituent, with carvone, 
menthol, menthone, isomenthone, linalool, estragole, borneol and cis- anethole. 
Other constituents are: tannins, sucrose, lipids, citric acid. 
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Orthosiphon stamineus 
folium 
 
 
 
Toxic 
component 
Approach Remarks 
Acceptable 
amount 
UF 
/ 
PDEoral 
LHRDoral 
Based on decreased ALT and/or AST levels, it is 
concluded that the extracts possess beneficial 
effects on the liver. This statement cannot be 
supported, because the biological significance (e.g. 
dose- relationship) and the cause of these effects 
were not investigated. For example, potential 
causes of decreased serum activities of ALT and 
AST are reported to include: decreased 
hepatocellular production or release of the 
enzymes, inhibition or reduction of the enzyme’s 
activity, interference with the enzyme assay 
50 mg/day 
832,5 mg25 
750 mg26 
5000 (PDE) 
 
 
References: 
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48 (11): 1711-1719. 
 
                                                      
25 Dry extract (solvent: ethanol 70% V/V, DER 7-8:1) 
26 powder 
[23, 24] On the German and Belgian market as “well-established use” 
Main components 
 
The most characteristic compounds are minerals (potassium 3%), diterpenes (orthosiphols A-E 
0.2%), triterpenes, essential oil, (0.02 -0.06%) (sesquiterpenes), lipophilic flavones like sinensetin 
(0.1 – 0.19%), isosinensetin and eupatorin flavonol glycosides; rosmarinic acid (0.1 – 0.5%), and 
other caffeic acid depsides like mono and dicafeyl tartric acid as well as lithospermic acid, 
pytosterols as b-sitosterol and up to 0.7% of essential oil, isositol, pimarane, isopimarane and 
staminane diterepnes, triterpenes and chromenes. 
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Peumus boldus 
folium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toxic 
component 
Approach Remarks Acceptable amount UF 
ascaridole 
NOELhuman oral 
NOELtotal alkaloids human oral 
NOELboldine human parenteral 
NOELboldine human oral 
PDEascaridole  
Doses of 50 mg/kg/day did not 
produce any significant changes 
over the 90-day period. Neither 
the boldo extract nor boldine 
caused any overt signs of toxicity 
in the heart or kidneys but 
steatosis was observed in two 
animals at doses of 800 mg/kg 
 
Ascaridole is highly toxic and this 
raises concerns about the 
suitability of boldo leaf in 
traditional herbal medicinal 
products. 
 
0.1% of total alkaloids, expressed 
as boldine 
(C19H21NO4) 
 
2-4% of volatile oil. Major 
constituents reported as: 
ascaridole (16-38%), 1,8 cineole 
(11-39%) and p-cymene (9-29%) 
75 mg/Kg b.w./day 
10,5 mg/Kg b.w./day 
6,25 mg/Kg b.w./day 
12,5 mg/Kg b.w./day 
0.004 mg/Kg/day 
2000 (ethanolic 
extract oral) 
2000 (total alkaloids 
oral) 
2000 (boldine 
parenteral) 
2000 (boldine oral)  
5000 (ascaridole PDE) 
 
References: 
• Levy-Appert-Collin M-C, Levy J. Sur quelques preparations galeniques de feuilles de Boldo (Peumus boldus, 
Monimiacees J Pharm Belg 1977; 32: 13-22 
• Magistretti MJ. Remarks on the pharmacological examination of plant extracts. Fitoterapia 1980; 51:67-79. 
• Kreitmar H. Pharmakologische wirkung des alkaloids aus Peumus boldus Molina. Pharmazie 1952; 
7: 07-511.  
• Opdyke DL. Monographs on fragrance raw materials: Boldo oil. Food and Chemical Toxicology 1982; 
20 (Suppl.6): 643-644. 
 
 
Main components 
Alkaloids: Isoquinoline-type 0.25-0.7%. Boldine, isoboldine, 6a, 7-dehydroboldine, isocorydine, 
isocorydine-N-oxide, norisocorydine, laurolitsine, laurotetanine, N-methyllaurotetanine, reticuline, 
(-)-pronuciferine, sinoacutine. Boldine is usually the major alkaloid (reported as 14-36% of total 
alkaloids).  
Volatile oil: 2.0-2.6% (Vogel et al., 1999). Major constituents reported as: ascaridole (16-38%), 1,8 
cineole (11-39%) and p-cymene (9-29%) (Bradley, 2006).  
principal components of the oil are determined genetically and have reported levels: ascaridole 
(34.6%), p-cymene (3.9%), 1,8-cineole (0.5%). Other constituents include: α-pinene, camphene, β-
pinene, sabinene, Δ3-carene, terpinolene, limonene, γ-terpinene, 2-nonanone, fenchone, 1-
methyl-4-isopropenylbenzene, α-fenchol, terpinen-4-ol, α-terpineol and methyl eugenol  
Polyphenols & Flavonoids: proanthocyanidins, flavonol glycosides: quercetin glycosides, 
kaempferol derivatives, isorhamnetin glycosides, phenolic acids, caffeoylquinic acid glycoside and 
proanthocyanidins. Isorhamnetin glucosyl-di-rhamnoside was the most abundant flavonol 
glycoside in the male boldo sample, whereas isorhamnetin di-glucosyl-di-rhamnoside was the main 
phenolic compound in female boldo leaves infusion 
Other constituents: coumarin, resin, tannin.  
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Pimpinella anisum 
seeds and oil 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toxic component Approach Remarks Acceptable amount UF 
Trans-anethole NOEL human oral 
Trans-anethole exerted 
dose-dependent anti-
implantation activity after 
oral administration to 
aduIt female rats on days 
1-10 of pregnancy 
 
In 90-day experiments in 
rats, 0.1% trans-anethole 
in the diet induced no 
toxic effects, whereas a 
dose-related oedema of 
the liver was reported at 
levels between 0.3 and 
3.0% 
1,25 mg/Kg b.w./day 2000 
 
 
References: 
 
• European Pharmacopoeia 7th ed., Aniseed - Anisi fructus. Council of Europe. 1/2012: 0262; 3858- 3859.  
• Hagan EC, Hansen WH, Fitzhugh OG, Jenner PM, Jones WI, Taylor JM et al. Food flavourings and compounds 
of related structure. II. Subacute and chronic toxicity. Food Cosmet Toxicol 1967, 5: 141- 157.  
• JECFA: Joint FAO/WHO Expert Committee on Food Additives. Safety evaluation of certain food additives. 
Trans-anethole. WHO Geneva, 1999.  
• Le Bourhis B. Propriétés biologiques du trans-anethole. Essai de détermination de la dose journalière 
acceptable. Parfums Cosmet Sav Fr 1973, 3: 450-456.  
• Lin FSD. Trans-anethole. In: Joint FAO/WHO Expert Committee on Food Additives. Toxicological evaluation of 
certain food additives and contaminants. WHO Food Additives Series 28. WHO Geneva, 1991: 135-152. 
• Samojlik I, Mijatović V, Petković S, Skrbić B, Božin B. The influence of essential oil of aniseed (Pimpinella 
anisum, L.) on drug effects on the central nervous system. Fitoterapia 2012. 
 
Main components 
The essential oil, obtained by steam distillation of crushed fruits, varies between 1.5% and 
6% and contains mainly trans-anethole (80-95%) 
 
Trans-anethole 76.7- 93.0% 
Estragole 0.5- 6.1% 
Anisaldehyde 0.1- 3.5% 
Linalol 0.1- 1.5% 
Alpha-terpineol 0.1-1.5% 
Cis-anethole <0.5% 
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Plantago ovata 
seminis tegumentum 
 
 
 
 
 
 
 
 
 
 
 
Toxic 
component 
Approach Remarks Acceptable amount UF 
/ 
LHRDoral 
 
 
The data available support the use of Plantago ovata, 
seminis tegumentum as laxative and as an adjuvant to 
diet in hypercholesterolemia, even if the mechanism is 
not fully understood. 
The non-clinical data on toxicology of P. ovata 
preparations are incomplete, but available data indicate 
no signals of toxicological concern 
There are only unpublished data (e.g. LD50=3360 mg/Kg in 
rats) available concerning Plantago ovata, (semini 
tegumentum) and psyllium without an exact definition of 
the test preparation. however, given the composition, no 
toxicity concern is expected. 
3200 mg27  
 
/ 
 
 
References: 
 
• Attaluri A, Donahoe R, Valestin J, Brown K, Rao SSC. Randomised clinical trial: dried plums (prunes) 
vs. psyllium for constipation. Aliment Pharmacol Ther 2011, 33:822-828 
• Chouinard LE. The role of psyllium fibre supplementation in treating irritable bowel syndrome. Can J Diet Pract Res 
2011, 72(1): e107-114  
• Federal Register. The Daily Journal of the United States Government. Rule. Laxative Drug Products for Over-the-
Counter Human Use; Psyllium Ingredients in Granular Forms. A Rule by the Food and Drug Administration on 
03/29/2007  
• Marlett JA, Kajs TM, Fischer MH. An unfermented gel compound of psyllium husk promotes laxation as a lubricant 
in humans. Am J Clin Nutr 2000, 72(3):784-789 
• Study 6114-184, 187, 188. Procter & Gamble. Subchronic toxicity in the rat. Pharmaco-toxicological expert report 
for Metamucil, January 2001 
• Turley SD, Daggy BP, Dietschy JM. Psyllium augments the cholesterol-lowering action of cholestyramine in 
hamsters by enhancing sterol loss from the liver. Gastroenterology 1994, 107(2):444-452 
 
 
 
 
                                                      
27 On the Belgian market, as “well-established use” - granules since 1963; powder since 1984  
Main components 
 
Plantago ovata, seminis tegumentum consists of 85% water-soluble fibre. The active 
polysaccharidic fraction comprises 65% D-xylose, 20% L-arabinose, 6% rhamnose and 9% 
D-galacturonic acid. The polysaccharide is shown to be a highly branched acidic 
arabinoxylan, the xylan backbone having both 1→4 and 1→3 sugar linkages. 
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Polygonum aviculare 
herba 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toxic 
component 
Approach Remarks 
Acceptable 
amount 
UF 
Naphthoquinone 
Umbrelliferone 
TTC 
 
Germany 
Pharmaceutical form: herbal tea containing (in 1 sachet 
(1.6 g)): 240 mg Foeniculi amari fructus, 208 mg Thymi 
herba, 192 mg Tiliae flos, 192 mg Polygoni avicularis 
herba, 176 mg Lichen islandicus, 96 mg Primulae flos, 
64 mg Lamium album flos, 64 mg Verbascum thapsus 
flos 
Indication: traditional herbal medicinal product to 
liquefy mucus. Posology: 4-6 times daily 1 cup of tea (1 
sachet/cup) On the market since: at least 1978 [only as 
combination products therefore this information 
cannot sustain the safety and thus is reported as 
additional information.] 
Only few toxicological data are available, with an 
adequate risk assessment, for each compound, the TTC 
could be set on 1800 µg/day 
540 µg/day / 
 
 
References: 
 
• European Pharmacopoeia 8h ed. Knotgrass – Polygoni avicularis herba. Council of Europe. 07/2013: 1885 
• Kazemivash N, Jamali M. Investigation of cytotoxic effects of methanolic total extract of the aerial part of 
polygonum aviculare L. in vegetative and generative phase on nalm-6 (pre-B-cell leukaemia) cell line. Journal of 
Biology and Today’s World 2013, 11:506-508  
• Roman I, Rusu MA, Puică C, Borşa M. [Emphasis of some preparate of Polygonum action on the vital organs in 
laboratory animals]. Annals of the Romanian Society for Cell Biology 2008, 13:183-198 
• EMA/HMPC/143659/2015 
 
 
Main components 
 
Tannins (3.5-4%): rhatannin, gallo- and catechol tannins  
Phenolic carboxylic acids: caffeic, chlorogenic, gallic and protocatechuic acids  
Naphthoquinone: 6-methoxyplumbagin 
Hydroxycoumarins: umbelliferone, scopoletin 
Lignans: lignin glycoside, aviculin 
Sterols: mainly β-sitosterol 
Saponins: triterpenoid saponins, mostly oleanolic acid  
Anthraquinones: emodin 
Silicic, tartaric and formic acids (1%): present as water-soluble silicates  
Carbohydrates: glucose, galactose, arabinose, sucrose, rhamnose, galacturonic acid  
Other constituents: essential oils, carotene, vitamins C and K 
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Potentilla erecta 
rhizoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toxic 
component 
Approach Remarks 
Acceptable 
amount 
UF 
/ 
PDEoral 
PDEoral 
The medicinal use of Potentilla erecta, rhizoma can 
be traced in literature back to the 15th century. 
Potentilla erecta, rhizoma is traditionally used for 
acute, unspecified diarrhoea, externally for 
haemostasis, mild inflammation of the oral and 
pharyngeal mucosa, prosthetic pressure points, 
frostbite, burns, haemorrhoids and poorly healing 
wounds  
 
The Danish Food Agency has accepted 200 mg 
Potentilla erecta, radix in a food supplement. This is 
not an upper limit but a specific assessment in a 
specific case. 
 
Risk – benefit  
Since no specific risks are known regarding the oral 
and oromucosal use of herbal preparations of 
Potentilla erecta, there are no limitations from the 
herbal preparation when used in adults. 
145 mg/day 
(A dry extract 
prepared by 
maceration with 
water) 
12,5 mg/day 
(extraction solvent 
acetone/water 
75:25) 
5000 
1200 
 
 
References: 
 
• European Pharmacopoeia 6.0. Tormentil tincture – Tormentillae tinctura. Council of Europe. 01/2008: 1895  
• Lund K, Rimpler H. Tormentil rhizome: isolation of an ellagitannin and pharmacological screening. Dtsch Apoth Ztg 
1985, 125:105-08 
• Madaus G. Lehrbuch der biologischen Heilmittel. Georg Thieme Verlag, Leipzig 1938 
• Shushunov S, Balashov L, Kravtsova A, Krasnogorsky I, Latte KP, Vasiliev A. Determination of acute toxicity of the 
aqueous extract of Potentilla erecta (tormentil) rhizomes in rats and mice. J Med Food 2009, 12:1173-76 
• Huber R, von Ditfurth A, Amann F, Güthlin C, Rostock M, Tritler R, Kümmerer K, Merfort I. Tormentil for active 
ulcerative colitis. J Clin Gastroenterol 2007, 41:834-38 
 
Main components 
 
Tannins: 15-22% total tannins (15-20% condensed tannins, about 3.5% hydrolysable 
tannins) 
Flavonoids: kaempferol, cyanidinglucoside and leucoanthocyanidin and the tannin 
monomers catechin, epicatechin, gallocatechin and epigallocatechin 
Phenol carboxylic acids: p-coumaric acid, 3,4-dihydroxybenzoic acid, gallic acid, sinapic 
acid and caffeic acid 
Triterpene saponins: quinovic acid, tormentillic acid and tormentosid 
Fatty acids: in extracts prepared with supercritical CO2 the following constituents are 
found: lauric acid, linoleic acid, linolenic acid, palmitic acid, palmitoleic acid, 
pentadecanoic acid, stearic acid and oleic acid. 
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Prunus africana 
cortex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toxic 
component 
Approach Remarks 
Acceptable 
amount 
UF 
/ 
PDEoral 
LHRDoral 
France “well-established use”: Soft extract; Solvent: 
stabilised chloroform; DER 114-222:1 (stabilised by 
1.2% of ethanol >99.9%) since 1969 
Indication: Treatment in miction moderate disorders 
connected with benign prostatic hyperplasia (BPH). 
Posology: A capsule twice daily. A capsule contains 50 
mg of extract. 
Duration of use: 6 weeks (+ 2 weeks) 
75 mg/day 
100 mg  
500 (PDE) 
 
 
References: 
 
• Andro MC, Riffaud JP. Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia: a 
review of 25 years of published experience. Curr Ther Res 1995, 56:796–817 
• Bombardelli E, Morazzoni P. Prunus africana (Hook f.) Kalkm. Fitoterapia 1997, 68:205-218 
• ESCOP Monographs 2nd ed. Pruni africanae cortex – Pygeum bark. European Scientific Cooperative on 
Phytotherapy, editor. Thieme Verlag, Stuttgart Supplement 2009, 206 
• European Pharmacopoeia. 8th ed. Pygeum africanum bark - Pruni africanae cortex. Council of Europe. 
1/2015:1886 
• Schleich S, Papaioannou M, Baniahmad A, Matusch R. Activity-guided isolation of anantiandrogenic compound of 
Pygeum africanum. Planta Med 2006a, 72(6):547-551 
• Schleich S, Papaioannou M, Baniahmad A, Matusch R. Extracts from Pygeum africanum and other ethnobotanical 
species with antiandrogenic activity. Planta Med 2006b, 72(9):807-813 
• Verschaeve L, Kestens V, Taylor JLS, Elgorashi EE, Maes A, Van Puyvelde L, et al. Investigation of the antimutagenic 
effects of selected South African medicinal plant extracts. Toxicology in Vitro 2004, 18(1):29-35 
• WHO Monographs on Selected Medicinal Plants. Vol 2. Pygeum africanum. World Health Organization, Geneva 
2009, 83-91 
 
 
Main components 
 
phytosterols (approximately 0.05%), e.g. beta-sitosterol, beta-sitosterol 3-glucoside and 
beta- sitostenone, free C, -C 24 fatty acids, pentacyclic triterpenic acids are present (14%) 
(ursolic and oleanolic acid derivatives) and long chain aliphatic alcohols (n-docosanol, n-
tetracosanol and their trans-ferulic acid esters)  
The proposed active constituents of a lipophilic extract of Pruni africanae cortex include 
docosanol (0.6%) and beta-sitosterol (15.7%).  
alkanols (tetracosanol [0.5%] and trans-ferulic acid esters of docosanol and tetracosanol), 
fatty acids (which are 12-24 carbons in length, 62.3%, comprising myristic, palmitic, 
linoleic, oleic, stearic, arachidic, behenic and lignoceric acids); sterols (sitosterone [2.0%] 
and daucosterol) and triterpenes (ursolic acid [2.9%], friedelin [1.4%], 2-a-hydroxyursolic 
acid [0.5%], epimaslinic acid [0.8%] and maslinic acid) 
Tannins. 
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Rhodiola rosea 
 rhizoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toxic 
component 
Approach Remarks 
Acceptable 
amount 
UF 
α-pinene 
 
LHRDoral 
 
Hellum et al. 2010 report a considerable variability between 
clones of Rhodiola rosea in Norway based on data obtained from 
ethanolic extracts (primary extraction solvent ethanol 96%). 
Irrespective of the plant origin (cultivated in Lithuania or 
naturally occurring in Altai mountains). Kucinskaite et al. (2007) 
found in aqueous- ethanolic extracts 1.35-1.62 mg/ml of 
salidroside, while the profile of rosavins differed considerably. 
Ethanol 70% v/v yields extracts with a low content of salidroside 
compared to ethanol 40% v/v; in contrast rosavins are more 
efficiently extracted by ethanol 70% (Kucinskaite et al. 2007).  
The clinical trials as well as the traditional use do not give 
reasons for special safety concerns. No serious adverse events 
are reported. The in vitro observed inhibition of CYP3A4 and P-
glycoprotein was not confirmed in vivo. Additionally, no case 
reports on interactions are published. Because of the limited 
duration of use of 2 weeks, the in vitro data seem to be of minor 
clinical relevance.  
400 mg/day28 / 
 
References: 
 
• Battistelli M, De Sanctis R, De Bellis R, Cucchiarini L, Dacha M, Gobbi P. Rhodiola rosea as antioxidant in red blood 
cells: ultrastructural and haemolytic behaviour. Eur J Histochem 2005, 49(3):243-54.  
•  Burgos R, Hancke J. Long-term toxicity test. 3 months subchronic toxicity test for Sedum rosea. Swedish Herbal 
Institute, Gothenburg, Sweden, 1991 unpublished results.  
• EMA/HMPC/232100/2011  
• Hellum BH, Tosse A, Hoybakk K, Thomsen M, Rohloff J, Georg Nilsen O. Potent in vitro inhibition of CYP3A4 and P-
glycoprotein by Rhodiola rosea. Planta Med 2010, 76(4):331-8.  
• Kucinskaite A, Poblocka-Olech L, Krauze-Baranowska M, Sznitowska M, Savickas A, Briedis V. Evaluation of 
biologically active compounds in roots and rhizomes of Rhodiola rosea L. cultivated in Lithuania. Medicina (Kaunas) 
2007, 43(6):487-94.  
• Zhu J, Wan X, Zhu Y, Ma X, Zheng Y, Zhang T. Evaluation of salidroside in vitro and in vivo genotoxicity. Drug Chem 
Toxicol 2010, 33(2):220-6. 
                                                      
28 On the italian market as “taditional use” – 200 mg dry extract 
Main components 
Phenylalkanoids: Phenylethanoids (e.g salidroside [syn. rhodioloside]: p-hydroxyphenylethyl-O-
ß- D-glucopyranoside), phenylpropenoids (e.g. rosin: cinnamyl-O-ß-D- glucopyranoside; rosarin: 
(cinnamyl-(6’-O-α-L-arabinofuranosyl)- O-ß-D- glucopyranoside; rosavin: (cinnamyl-(6’-O- α-L- 
arabinopyranosyl)- O-ß-D- glucopyranoside), phenylpropanes (e.g. tyrosol). Only limited data are 
available regarding the quantitative composition  
Essential oil: The dried rhizome contains approximately 0.05% of essential oil. Main components 
are α-pinene, geraniol, limonene, ß-phellandrene, linalool, n-octanol, n-decanol, dodecanol, 1,4-
p- menthadien-7-ol.  
Monoterpene derivatives: rosiridol, rosiridin, rhodiolosides A-E.  
Cyanogenic glycosides: rhodiocyanoside A, lotaustralin  
Proanthocyanidines: prodelphinidine-gallate esters  
Flavonolignans: rhodiolin  
Flavonoids: Rhodiola-specific flavonoids like rhodionidin, rhodiolgin, rhodalidin, rhodionin, 
rhodiolgidin, rhodalin, rhodiosin; tricin and kaempferol derivatives.  
Phenolic acids: chlorogenic acid, hydroxycinnamic acid. 
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Viscum album 
 herba 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toxic 
component 
Approach Remarks Acceptable amount 
ML I 
ML II 
ML III 
 
PDEViscum extract i.v. 
PDEViscum juice parenteral 
PDEViscotoxins i.v. 
 
Even if in Germany there are some authorized products 
made from Viscum album (various preparations) due the 
route of administration, the uncertain balance of risk-
benefit, the lack of toxicity data and the high toxicity of 
some come compounds, the LHRD approach can’t be used 
to sustain the safety of the product. 
 
5,83 10-4 mg/die 
3,73 10-5 mg/die 
1,16 10-9 mg/die 
 
 
 
References: 
 
 
• Barnes J, Anderson LA, Philipson JD. Herbal medicines. 3rd edition. Pharmaceutical press 2007, 436-46. Available at 
the EMA-library  
• Doehmer J, Eisenbraun J. Assessment of Extracts from Mistletoe (Viscum album) for Herb–Drug Interaction by 
Inhibition and Induction of Cytochrome P450 Activities. Phytother Res 2012, 26(1):11- 17, doi 10.1002/ptr.3473  
• EMA/HMPC/246778/2009 
• Hänsel R, Keller K, Rimpler H, Schneider G. editors. Hagers Handbuch der Pharmazeutischen Praxis.  
Springer-Verlag, Berlin 1994, 1160-1179 
• Kienle GS, Kiene H. Die Mistel in der Onkologie - Fakten und konzeptionelle Grundlagen. Schattauer Verlag, 
Stuttgart, New York, 2003  
• Stein GM. Toxicology of mistletoe and their components. In: Büssing A, editor. Mistletoe. The Genus Viscum. 
Hardwood Academic Publishers, Amsterdam 2000, 183-194  
 
  
Main components 
Viscum lectins (ML I, ML II,ML III; glycoproteins with the ability to bind specifically to galactose, 
N-acetylgalactosamine and cell surfaces), proteins and polypeptides (in particular the viscotoxins 
which are composed of 46 amino acids), phenylpropanes and lignans, caffeic acid derivatives, 
flavonoides (especially derivatives of quercetin), biogenic amines (tyramine etc.), 
polysaccharides (particularly galacturonans and arabinogalactans), membrane lipids (vesicles) 
and other substances in low concentrations  
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DISCUSSION 
One of the first but still most used toxicological data, applied in calculation of others toxicological 
parameters (as PDE, NOEL, etc), is the LD50. The considerable differences among species are one of 
disadvantage to using animal LD50 data, as well as differences among strains within a species. A 
similar disadvantage exists in the context of risk assessment for chronic exposures. The general 
approach to address this disadvantage for chronic exposure risk assessment, in part, is to use the 
animal model that best represents humans. If it is unknown which animal is the best model to 
represent humans, then the most sensitive species should be used following the general rules 
applied by health Agencies in the world (Barnes, Dourson, 1988; U.S. EPA, 2002). A similar 
approach was used here extrapolating from animal LD50 data. This approach has the advantage of 
being health-protective, although it may not be very accurate. A first approximate on in assessing 
accuracy of any risk extrapolated from experimental animal data to humans is that if experimental 
results indicate similar toxicities among different animal species, it is likely that the toxicity will be 
more similar for humans. Therefore, comparison of the mouse and rat LD50 values may provide 
some insight as to the accuracy of the estimate for humans.  
The first example here reported is related to products obtained from Rodhiola rosea L. for oral 
administration. The phytochemistry of this species have been well characterized and it has a very 
low toxicity (Assessment report on Rhodiola rosea L., rhizoma et radix). Current toxicity studies 
indicate its LD50 as about 28.6 ml/kg, or about 3360 mg/kg (Brown et. al. 2002). For perspective, 
such dosage in a 70 kilograms man would be 235 g or 235.000 mg. Since most recommended 
doses are about 100 to 400 mg and the total recommended dosage for an entire day rarely 
exceeds 600 to 1000 mg, you can see there is a very large margin of safety, much larger than with 
apparent. 
Table 1  
Example of calculation of the different toxicological parameters for the plant with low toxicity 
Rhodiola rosea L. 
 
BW= body weight 
OS = Oral Somministration 
NOELrat = 3360 *0,4Kg/200 
NOELhuman= 3360*60Kg/2000 
PDE= 6,72*50/5*10*10 
Rhodiola rosea L.  Compound  LHRD TTC PDE NOELrat NOELHuman 
OS Rosavin 
200 mg 
(as dry extract) 
540 µg/day 0,672mg/die 6,72 mg/Kg*bw/day 100,8 mg/Kg*bw/day 
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This plant belonging to the Crassulaceae family and its main component is rosavin. This species is 
used for temporary relief of symptoms associated with stress, fatigue, exhaustion and mild anxiety 
states and it was authorized in EU as medicinal product. As shown in the table 1 is possible to 
assess the safety of products containing herbal preparation of Rhodiola rosea L. using different 
approaches based on different parameters; in this case it is preferable to choose the LHRD 
approach considering that it is on the market in EU as medicinal product and toxicological data 
(LD50) shown a trifling toxicity profile. I want to underline that, as is showed in the table, the 
calculation of TTC, PDE and NOEL value is related to the compound rosavin only whereas, the 
LHRD is relates to the dry extract (extraction solvent ethanol 60% V/V). Given the extensive use of 
the product and the time on the market as well the same route of administration the LHRD as it is, 
is enough to assess the safety. Sometimes this approach needs some adjustments and one this 
example is the value LHRD/100, this kind of approach is suggested in the in the art.14 of the 
Directive 2001/83/EC in the contest of the regulation of the homeopathic medicinal products. 
 
The second example concerns a high toxic herbal drug largely used in popular medicine such as 
Viscum album L., a species of the Santalaceae, family commonly known as European mistletoe, 
common mistletoe or simply mistletoe. The toxicity data used to calculate the parameters in the 
table 2 are available in the document “Assessment report on Viscum album L., herba”29  
Table 2 
Example of calculation of the different toxicological parameters for the plant with high toxicity 
Viscum album L.  
 
 
Bw = Body weight 
IP = Intraperitoneally 
IV = Intravenously 
 
                                                      
29 EMA/HMPC/246778/2009 
 
Viscum 
album L.  
Compound LHRD TTC PDE NOELmice NOELHuman 
IV Viscum extract / 0,15 µg/day 
5,83 10-4 
mg/die 
0,14 
mg/Kg*bw/day 
17,5 mg/Kg*bw/day 
IP Viscum juice / 0,15 µg/day 
3,73 10-5 
mg/die 
0,00896 
mg/Kg*bw/day 
1,12 mg/Kg*bw/day 
IP Viscotoxins / 0,15 µg/day 
2,91 10-7 
mg/die 
0,00007 
mg/Kg*bw/day 
0,0175 mg/kg*bw/day 
IV Viscotoxins / 0,15 µg/day 
1,16 10-9 
mg/die 
0,000014 
mg/Kg*bw/day 
0,035 mg/kg*bw/day 
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The Viscum album L. juice contains a mixture of different compounds, one of which is toxic. The 
Viscumin (Olsnes et al. 1982) is a cytotoxic protein (ribosome inactivating protein, or RIP) that 
binds to galactose residues of cell surface glycoproteins and may be internalized by endocytosis 
(Olsnes et al. 1982). Viscumin strongly inhibits protein synthesis by inactivating the 60S ribosomal 
subunit. The structure of this protein is very similar to other RIPs, showing the most resemblance 
to ricin and abrin. As is shown in the table 2 is possible to assess the safety using different 
approaches each of them is correct but take into account of different parameters; in this case, 
rating the well-known toxicity of this specie, it should be chosen the PDE’s most restrictive value 
(1,16 10-9 mg/die). Otherwise, if the finish product is made with the juice or the extract, their own 
PDE’s value could be used always taking into account that the final concentration of viscumin must 
be under its own PDE otherwise, an ad hoc toxicity study, concerning the product for which the 
authorization is required, should be provided. Remembering that, the PDE approach is suggested 
in the ICH guidelines on solvents and impurities so it’s something that we want to avoid in the 
finished product (like residues and impurities). 
 
Another example of herbal drug widespread used in medicine is the Aesculus hippocastanum L. 
extract and its isolated compound aescin. 
Table 3 
Example of calculation of the different toxicological parameters for the Aesculus hippocastanum L. 
 
 
BW = Body weight 
IP = Intraperitoneally 
OS = Oral somministration 
 
Aesculus 
hippocastanum L. 
Compound LHRD TTC PDE NOELmouse NOELhuman 
IP Esculetin^ / 
0,15 μg/day 
(IP) 
0.017 mg/die 0,406 mg/Kg*bw/day 50,75 mg/Kg*bw/day 
OS Esculetin^ / 540 μg/day 0.023 mg/die 0,56 mg/Kg*bw/day 70 mg/Kg*bw/day 
IP Esculin^^ / 
0,15 μg/day 
(IP) 
0.022 mg/die 0,532 mg/Kg*bw/day 66,5 mg/Kg*bw/day 
OS Aescin 40 mg 540 μg/day 0.001925 mg/die 0,0462 mg/Kg*bw/day 5,775 mg/Kg*bw/day 
IV 
Aescin  
 
1 mg/ml 0,15 μg/day 7.81 10-5 mg/die 
0,00186 
mg/Kg*bw/day 
0,2345 mg/Kg*bw/day 
OS 
Aesculus 
hippocastanum L., 
extract 
400 mg 540 μg/day 0.01238 mg/die 
0,297 
mg/Kg*bw/day 
29,7 mg/Kg*bw/day 
IP 
Aesculus 
hippocastanum L., 
extract 
/ 540 μg/day 0.6875 10-3 mg/die 0,0165 mg/Kg*bw/day 1,375 mg/Kg*bw/day 
IV = Intravenously 
^= Esculetin (6,7-dihydroxycoumarin) 
^^= Esculin (6-(β-D-glucopyranosyloxy)-7-hydroxy-2H-1-benzopyran-2-one, or 6,7 dihydroxycoumarin 
6-glucosid) 
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Aesculus hippocastanum L. belongs to the Hippocastanaceae family and its common name is horse 
chestnut. Native to Western India, today the horse chestnut is widely distributed all over the 
world and it grows in Iran, Northern India, Asia Minor, Europe and USA (Bombardelli et al. 1996). It 
is a 25-30 mt. high tree (Bézanger-Beauquesne et al. 1980). The most used part is the bark that is 
obtained from the young branches and dried. The composition of horse chestnut bark is complex. 
The main compounds are coumarin derivate (up to 7%) (Wichtl et al. 2003) Glucosides: Esculin, a 
glucoside of esculetin, Fraxin a glucoside of fraxetin; Scopolin, a glucoside of scopoletin. Other 
constituents are: tannins (up to 2 %) (P. Fournier 1948; M. Paris, H. Moyse 1981), flavonoids, 
anthocyanins (Bombardelli et al. 1996), catechins derivatives (Bombardelli et al. 1996; Wichtl et al. 
2003), traces of aescin (cortex) (Wichtl et al. 2003; Schneider 1978). Aescin, the major active 
principle from aesculus has shown satisfactory evidence for a clinically significant activity in 
chronic venous insufficiency (CVI), haemorrhoids and post-operative oedema (Sirtori 2001). This 
shown and help us to understand that many studies have been carried out on this pool of 
substances and they are still extensively used in therapy until today. For all those reasons, the 
safety could be assessed on the LHRD approach respectively in the dose of 40mg for the oral 
administration and 1 mg/ml for the slow intravenous administration. It is important to note that, 
for regulatory purposes and not only, it is always important to provide the rationale underlying the 
choice of value rather than another. In addition, it is necessary to specify that if the product in 
safety assessment is a plant extract and therefore, depending on whether it is an alcoholic, water 
or hydroalcholic extract we may have more or less all phytocomplex and not just aescine, it is 
more appropriate to take NOEL human as it results from a more representative datum. However, 
on the French market is authorized as “traditional use” a product made with the cortex dry extract 
(solvent water, DER 5-6: 1) of Aesculus hippocastanum L. with a posology 200 mg of extract two 
times daily, that could be used as LHRD for a water extract.  
 
The last example concerns a product containing Avena sativa L. commonly named oat used both 
for medicine and as food. The characterization of the phytochemistry is reported in the document 
EMEA/HMPC/202967/2007, based on it we could say that all the parts of the plant contain the 
active principles but the main potentially toxic compounds are avenanthramide and saponins 
avenacoside A and B. However, avenacoside A oat saponins was 0.04% of dry matter and 
avenacoside B was 1% of dry substance as determined by thin layer chromatography (TLC) and the 
toxic effects of many saponins are neutralized in the mouth of animals such as sheep intestinal 
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bacteria and rumen bacteria (by saliva). Cooking or heat processing can also detoxify saponins. 
They are highly toxic when given intravenously (Harsha K. et al 2012). In addition, in the document 
“Scientific Opinion on the substantiation of a health claim related to oat beta-glucan and lowering 
blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation 
(EC) No 1924/2006”, we could find two methanalisys from which is possible to know that “The 
estimated daily consumption of oat beta-glucan amounted to 1.1-7.6 g/day, with a mean dosage 
of 3.7 g/day. The sources of oat beta-glucan included oat bran, oat meal and rolled oats, which 
were consumed as breakfast cereals, biscuits, bread, muesli, muffins, and powders. The 
intervention periods of the studies varied from 2.5 to 12 weeks, with a mean intervention period 
of 5.5 weeks.”; from this is clearly possible to understand that 3,7 g/day could be assumed as ADI 
and 1,1 g/day as LHRD. Concerning the saponins, of course, the intravenous route of 
administration must be excluded. 
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CONCLUSION 
 
The growing use of plant medicines in Europe needs a shared methodology to determine the 
toxicity and daily exposure levels to these drugs. For this reason, the regulatory agencies of the 
various countries have undertaken a study that could meet popular uses and toxicological 
research in the various countries of the union. Fit for purpose of what has been analyzed so far, it 
is clear that it is possible to make a good assessment of the risk of exposure to a substance in the 
absence of an ad hoc toxicological study without neglecting safety. Indeed, it should be 
emphasized that often the statistical approach and the application of empirical uncertain factors 
leads to safety values below those that would result from an ad hoc toxicological study by virtue of 
its approximation. Moreover, the last direction of the European authorities and the scientific 
community is to reduce animal testing when predicted exposures to a chemical/herbal substance 
are below a level that would be associated with potential human health concerns, and the 
proposed approach, summarized for convenience in the decisions tree shown in Figure 2, could be 
helpful according this line of thoughts and no less important according to the principles of the 
“green chemistry” too (Anastas, Paul et al. (1998). It is highlight that the decision tree in the figure 
2 is designed in the prospective to have a harmonized choice between parameters that are often 
used in different areas (food, chemicals, etc), in agreement with the view of a European 
harmonization of the evaluation for products of herbal origin, which lead to an easier circulation 
of the latter on the market. 
 In addiction, it is stressed that the authorities can always benefit form special warnings, 
precautions for use and limitation of use, such as excluding a special population (children, elderly, 
etc.), to ensure maximum protection for individuals. 
Last remark is that the proposed method in not a way to skip the safety evaluation but it should be 
intended as a tool in the critical situation, a way to have a starting point for a risk assessment; is 
strongly supported that the reliability of a toxicological data is given by the risk assessment on 
itself and not merely on the data. Comes to mind when a generic drug has to show that is 
equivalent to the originator (branded) although most of time is easy to understand this, the 
equivalence must be demonstrated and dicussed. 
 
 
 
 
 86 
 
Fig 2: decision tree which help to choose the best and safer approach for the assessment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PDE 
YES 
A toxicity data is available (in scientific literature) 
The phytochemistry is 
characterized 
Is allowed as food  
TTC 
0,15 µg/day 
Food 
approach 
LD50 NOAELs 
LOAELs 
PDE 
The substance/s 
is/are already on 
the market 
The product is 
representative, is 
well known and has 
the same route of 
administration 
LHRD 
The product is not 
well known and/or 
has different route of 
administration 
LHRD/UF (Usually 100) 
 
The datum is 
representative, 
coming from a 
sturdy study and 
have the same 
route of 
administration 
The datum is not 
representative 
and/or the route 
of administration 
is different 
NOELHuman 
Assess each substance 
following the Cramer 
method 
NOELanimal 
TTC under 
Kroes R. et al 
method 
NO NO 
YES 
ADI, TDI, 
TDLo, etc. 
 
 
NO YES 
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